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ABSTRACT
FURTHER ADVANCES FOR THE SEQUENTIAL MULTIPLE
ASSIGNMENT RANDOMIZED TRIAL (SMART)

Tianjiao Dai, M.S.
Advisory Professor: Sanjay Shete, Ph.D.

Sequential multiple assignment randomized trial (SMART) designs have been
developed these years for studying adaptive interventions. In my Ph.D. study, I mainly
investigate how to further improve SMART designs and optimize the interventions for
each individual in the trial. My dissertation has focused on two topics of SMART designs.
1) Developing a novel SMART design that can reduce the cost and side effects
associated with the interventions and proposing the corresponding analytic methods. I
have developed a time-varying SMART design in which the time of the intervention
varies among participants and contains part of the information regarding the
intervention effect. We proposed two analytic approaches for analyzing the data from
this type of SMART design. Based on simulations, we suggest using joint modeling as a
data analysis method since it can well utilize the information of the intervention effect
contained in the treatment (also referred to as intervention) time and estimate the model
parameters better than the single mixed effect model. We also showed that the
vi

proposed time-varying SMART design is more efficient than the existing standard
SMARTs with respect to the cost and side effects associated with the interventions,
while maintaining the same power as the standard SMART design when selecting the
optimal embedded adaptive intervention.
2) Developing a new allocation strategy for SMART designs using a responseadaptive, covariate-balanced and optimal-decision-consistent randomization probability
under the Bayesian framework. This method applied the existing randomization
strategies in clinical trials to SMART designs by accounting for its special framework. In
addition, it takes into account the optimization of the individual’s intervention using a Qlearning approach in addition to being response-adaptive and balancing covariates
between competing interventions at each SMART stage. This approach also takes
advantage of the Bayesian framework. Using simulation studies, we compared the
proposed allocation strategy to other possible and existing allocation strategies in
clinical trials.
The research on SMART designs I conducted in my Ph.D. study will benefit the
community of researchers in the areas of clinical trial design and social behavioral
research. The novel design and analysis I proposed will increase the efficiency of
SMARTs in terms of the time and cost and reduce the side effects associated with the
interventions while promoting a better understanding of the optimal individualized
intervention strategy. The new randomization strategy I developed for SMART designs
increases the consistency of the optimal intervention strategy for each individual in the
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trial, which suggests an advantage over other existing randomization methods in clinical
trials that can be applied to SMART designs.
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1.1

Experimental designs in clinical trials
The design of experiments (DOE)(1-3) in clinical study is a formulation

process with the goal of assessing the efficacy(4-6), safety(7) and causal
mechanism(8,9) of medical products such as drugs or devices that are under
development or evaluation. It is often used as a “reference standard” when judging
all other types of designs. Specifically, in a DOE, we evaluate the effect of one or
more factors (also called variables or covariates) on one or more response
variables so that the data obtained can be analyzed to yield valid and objective
conclusions. For example, in a test of a new vaccine which is developed to
immunize people against the common cold, treatment condition (i.e., placebo or
vaccine) is the factor to be evaluated and the number of colds reported in each
treatment condition is the response variable. In the study of the effects of vitamin C
and vitamin E on health, dosage of vitamin C and vitamin E are the two factors to be
studied and the response variable is the number of days hospitalized, Usually, the
conditions of the experiment (i.e., the levels of factors) can be manipulated (e.g.
amount of dosage of vitamin C and vitamin E in the above example) and the factors
(e.g. individuals’ diet) that are not of primary interest to the research objectives are
controlled throughout the experiment while the results of the experiment are
unknown in advance. Research goals, target populations and sampling strategies
are specified before defining and conducting an experimental design. Key
components of an experimental design are the experimental unit (person or
community that is studied), types of variables (background, intermediate, primary
5

and uncontrollable), treatment structure (levels and combinations of treatments) and
design structure (define the grouping of the experimental units into clusters).
Generally, the data we observe or measurements we obtain are the additive
composite of the true level/value of the respondent on that measure and random
error by “true score theory”(10,11), which is analogous to signal and noise in
engineering. Experimental observations consist of the true effects of all variables on
an outcome (signal) and the random error from the experimental technique (noise).
Experimental designs are used to maximize the signal-to-noise ratio, i.e., enhance
the signal or reduce the noise to improve the research quality. Among all types of
experimental designs, factorial designs(12-16), randomized controlled trials(17-21)
(RCTs) and crossover designs(22-28) are three of the most commonly used
designs.
1.1.1 Factorial design
A factorial design is often used to study the combined effects of two or more
variables on an outcome by varying several factors simultaneously within a single
experiment. It is a useful analytic method for cases in which the factors are
interdependent. This type of design consists of several factors, each with discrete
levels or values, and experimental units that take on all possible combinations (full
factorial design(29-33)) or part of (fractional factorial design(12,15,34-38)) these
levels across all such factors. For example, we would like to study the two
intervention components-keeping a food diet(yes or no) and increasing activity(yes
or no) with a factorial design, the two factors ate the two interventions components
6

and each of them has two levels. Therefore, this is a 2 × 2 (or 22) factorial design.
Factorial designs are efficient for evaluating the effects of various combinations of
factors as well as their interaction effects in one study rather than conducting a
series of independent studies(39). However, factorial designs with more than two
factors or many levels may suffer some difficulty because of the large number of
different experimental conditions to manipulate. A meticulous plan is needed when
operating a factorial design as an error in one of the levels will jeopardize the whole
work.
1.1.2 Randomized controlled trial (RCT)
Instead of comparing individual conditions to each other as is the goal in a
factorial design, a randomized controlled trial(40-43) (RCT) is generally used when
there are only two or three experimental conditions and the primary research goal is
to directly compare the individual experimental conditions to each other. The twogroup experimental design(18,44,45) is the simplest form of RCT, and the two
groups are referred to as the experimental group and the control group. This type of
RCT is used to conduct a specific study of an intervention (e.g., a medicine,
therapy, diagnostic procedure, or surgical procedure) against a control (i.e., placebo
or best existing treatment) by randomizing patients between the two corresponding
groups. The primary interest of this type of design is to determine whether the two
groups are different after the clinical application. The comparison of the two groups
is based on the assumption that the two groups are comparable, which is ensured
by random assignment. A secondary goal of an RCT can be to identify factors that
7

influence the effects of the treatment(s) under study(46-48). The RCT has been
considered to be the gold standard for treatment evaluation over the past several
decades because of its advantages in reducing bias through good randomization,
producing results that can be analyzed with well-known statistical tools, and its clear
identification of participating individuals. However, the RCT also has drawbacks as
such trials are time- and cost-intensive(49), and have relatively poor performance in
assessing the benefit from complex interventions that account for individual
preferences or adherence, or in tailoring interventions to individual needs(50). In
addition, the traditional RCT ignores the cumulative information obtained during the
trial that can potentially be used to improve the results(50-53). RCTs do not allow
for the manipulation of subjects or interventions during the trial, which results in a
lack of heterogeneity and makes the results vulnerable to confounders. Over time,
the pre-fixed and unchanged treatments that are typically used in RCTs are being
replaced by adaptive interventions(54-56) in clinical and behavioral studies.
1.1.3 Crossover design
In the crossover design (22,57,58), each patient receives a different treatment
at a different time period during the trial. In contrast to a factorial design and most
RCTs, in which patients are randomized to a treatment and remain on that
treatment throughout the trial duration, patients in crossover designs switch from
one treatment to another during the trial. Crossover designs are often used to study
treatments to alleviate symptoms of a chronic and stable disease, with the
advantage of reducing the influence of confounding factors and reducing the sample
size while attaining the same level of statistical power or precision as other types of
8

designs(57). Although different treatments can be applied to the same patient in the
crossover design, the sequence of the treatments is determined before the trial is
conducted with a fixed time of administration for each treatment. Therefore, this
type of design is also non-adaptive and does not take into account the patients’
responses during the trial(58,59).

1.2

Adaptive intervention
Adaptive interventions(60,61) are developed to allow for greater

individualization and adaptation of intervention options than in the traditional fixedintervention approach that is typical of RCTs. In some statistical literature, adaptive
interventions are referred to as dynamic treatment regimes/regimens (DTRs)(6270), tailored treatment regimens(71) or adaptive treatment strategies(72). They are
operationalized as a sequence of decision rules that specify how intervention
options (e.g., type, intensity, dosage of treatment) should be adapted to an
individual's characteristics and changing needs as well as covariate history and
response at critical decision points during the course of care. With the goal of
optimizing the long-term effectiveness of the treatment, the interventions are
repeatedly adjusted over time because responses differ from person to person.
Adaptive interventions are particularly useful for chronic disorders for which there is
no uniformly or widely effective treatment because of their ability to accommodate
high heterogeneity in patients(66,72-75).

9

Compared to the commonly fixed interventions in RCT, in which the
composition and dosage of interventions are defined before the trial is conducted
and are offered uniformly to all participants, adaptive interventions can better
accommodate the individualized needs of patients and therefore have the potential
to be optimized. The major difference between fixed intervention and adaptive
intervention is that the adaptive intervention consists of not only the treatments, but
also other systemic components that can moderate the treatment effects
(76). In adaptive interventions, there is interdependency among treatments, factors
that moderate treatment effects, decision rules, and implementation of decision
rules. Therefore, for the cases where significant variation in treatment effects is
expected to be a function of identifiable tailoring variables, across participants
and/or within participants over time, an adaptive intervention can be employed as
an alternative approach to a fixed intervention. Conversely, if treatment effects do
not vary systematically across individuals, an adaptive intervention is unlikely to
show advantages over a fixed intervention.
There are four basic elements in an adaptive intervention: (1) intervention
stages: each beginning with a decision of intervention, (2) intervention options at
each stage regarding the types, dosages and other tactical options such as
augmenting, switching or maintaining, (3) tailoring variables that contain the
individual information that can be used for making decisions, and (4) a decision rule
that links the tailoring variable as the input to specific intervention options as the
output. There are typically two types of tailoring variables(77,78): (1) baseline
tailoring variables that include information regarding an individual’s characteristics
10

or information that is obtained before the first intervention stage, which can be used
at the first stage or at subsequent stages, and (2) intermediate tailoring variables
that are obtained during any decision stage and can be used to make decisions at
subsequent stages. There are generally three types of research aims(79) with
adaptive interventions: (1) evaluating a particular adaptive intervention; (2) finding
the best tailoring variables and/or decision rules; (3) implementing the decision rules
(i.e., testing or generating hypotheses to build an adaptive intervention).
Generally, adaptive interventions are developed with the goal of enhancing the
strength of the adaptive intervention and maximizing replicability. Specifically, a
well-designed intervention should include well-chosen and well-measured tailoring
variables, and should be able to produce the same results on different samples with
respect to the treatment effects(79). However, in practice, we usually do not have
sufficient empirical evidence or knowledge to build a high-quality adaptive
intervention for choosing the intervention stages, treatment options, useful variables
and decision rules. In order to obtain the optimal interventions for each individual,
sequential multiple assignment randomized trials (SMARTs)(80) are developed and
applied.

1.3

Sequential Multiple Assignment Randomized Trial (SMART)

1.3.1 Definition and empirical examples of the SMART design
SMART is the trial in which each individual goes through multiple stages with a
critical decision point corresponding to each stage. Specifically, it involves an initial
11

stage in which participants are randomized to all the available intervention options
such as different types of medical or behavioral treatments, followed by subsequent
stages in which some or all of the individuals are re-randomized to intervention
options available at that stage. Re-randomizations and intervention options at each
subsequent stage depend on the information obtained from previous stages such as
patient adherence or response status. Because the complexity of the SMART
design increases with the number of stages, a two-stage SMART is the most
commonly used design for its simplicity and ability to study various clinical
problems.
According to the extent and form of incorporated tailoring variables, a twostage SMART design can be categorized into the following four types(76). (1)
SMARTs with no embedded tailoring variables, in which the intervention strategies
are applied to all participants at the second stage regardless of any information
observed prior to the second-stage randomization. Interventions in this type of
design are actually non-adaptive because there are no embedded tailoring
variables. (2) A SMART study in which re-randomization to the second-stage
intervention options depends on an intermediate outcome, i.e., a participant is rerandomized or not in the second stage depending on his/her response status
(responder/non-responder) to the first-stage intervention. (3) SMARTs in which rerandomization to different second-stage intervention options depends on an
intermediate outcome, i.e., intervention options of the second stage are different for
responders and non-responders to the first stage. (4) SMARTs in which the
determination of whether to re-randomize or not depends on both an intermediate
12

outcome and prior treatment, which uses more information obtained before the
second stage than the other three types of SMARTs described here.
Several empirical examples that have used SMART designs are listed here:
(1) A study of smoking cessation(78) in which a two-stage SMART was conducted
to find an optimal multi-factor behavioral intervention to help smokers quit smoking
and follow-up strategies for them; (2) An adaptive treatment study of children with
attention deficit hyperactivity disorder (i.e., ADHD)(76,77,80), with the primary aim
of choosing the initial treatment between pharmacological and behavioral
interventions and the secondary aim of choosing a second-stage intervention for
children who have insufficient response; (3) A study of adaptive reinforcementbased treatment for pregnant drug abusers (RBT)(81,82) to choose an intervention
that intensifies, decreases, or is supplemented on the basis of patient response; (4)
A SMART design for comparing attendance-based prize contingency management
(CM) to treatment without incentives as well as testing the length and timing of
CM(83).
1.3.2 SMART and MOST
Multiphase Optimization Strategy (MOST)(84) was proposed by Collins et al. as
a new approach to systematically and efficiently optimize behavioral interventions.
MOST consists of three phases: a screening phase for selecting active intervention
components, a refining phase for fine tuning and optimizing the selected
components, and a confirming phase for evaluating the efficacy of the optimized
interventions. MOST, like SMART, is based on randomized experimentation.
Although MOST and SMART can be seen as two separate approaches for building
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optimal interventions for patients, SMART can also be integrated into MOST to
increase the potency of adaptive interventions. Because the refining phase in
MOST features the same goal as that of SMART, a SMART can be used to identify
the best adaptive intervention strategy by choosing the intervention types and
levels. The best adaptive intervention selected through a SMART is then tested
and evaluated by RCTs in the confirming phase of MOST.
1.3.3 Similarities and differences between SMART and other experimental
designs
As a relatively new type of experimental design, SMART has some similarities
to traditional designs (e.g., the factorial design and RCT). Although the
randomization in SMART designs permits an unbiased comparison, which is true of
the RCT and factorial design, it differs in terms of the actual conduct of the trial. In
particular, randomization in a SMART occurs repeatedly (e.g. 2 or 3 times) over
time to promote unbiased comparisons between the intervention components at
each stage for developing an adaptive intervention. In addition, restrictions based
on the intermediate outcome may apply to the randomization in SMART, which also
differs from that of the factorial design and RCT.
When compared to adaptive designs in a clinical study, SMART designs
involve different stages of intervention and/or experimentation and change based on
the accumulating data(85), which is similar to the adaptive designs with
prospectively planned time points for modification along the trial. However, the
SMART design is different from the adaptive design in many aspects. First, each
14

participant in a SMART goes through multiple stages of intervention; while each
stage in an adaptive design involves different participants. The application of a
SMART develops an optimal dynamic treatment regimen that can benefit
future patients; while adaptive designs mostly focus on the most efficacious
treatment based on the current knowledge available at the time a participant is
randomized to the trial. The sample size, randomization probabilities and
intervention options are pre-specified in the SMART, which is also different from the
adaptive design, in which the factors are adjustable for different groups of people in
the trial. Adaptations to interventions in SMART designs are made within the
participant; whereas adaptations to interventions in adaptive designs are made
between participants. However, despite the differences between the two types of
designs, elements in the adaptive design can be incorporated and used in the
SMART design(86,87).
SMART designs also have some operational similarity with classical crossover
trial designs(23,88) in which the patients cross from one treatment to another during
the course of the trial. However, they have different design structures because
crossover designs are typically used to contrast the effects of stand-alone
treatments; whereas SMART designs are used to develop a DTR. Additionally,
decisions of intervention options are typically made on the basis of the participants’
intermediate outcomes in the SMART design; whereas participants receive all the
candidate interventions in crossover trials. In a crossover trial, it is crucial
to exclude the carryover effects(59,89-91), whereas SMARTs make use of
carryover effects to construct optimal DTRs and improve the final outcomes.
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1.3.4 Advantages of SMART designs
The major advantage of the SMART design is that it facilitates the
development of high-quality adaptive interventions by allowing researchers to test
multiple potential adaptive interventions along with the available patient-specific
variables. In SMART, interventions for participants are time-varying according to the
information accumulating during the trial. Several critical decision points are built
into the trial, each of which corresponds to a separate stage of intervention. The
effectiveness of each stage can be assessed as the participants are randomized
multiple times. Several adaptive interventions embedded within a SMART can be
tested and the patient-specific variables can be assessed in relation to the
intervention components in the same trial. All these features have increased the
popularity of SMART designs in real-world clinical studies particulary for chronic
disorders, as they allow clinicians to develop the best decision rules based on
research rather than a priori decisions, which is the strategy applied in the
traditional two-arm RCT. SMART designs can effectively accommodate
heterogeneous samples as well as baseline measures and time-varying factors.
In a multiple arm, one-stage-at-a-time, randomized trial, synergistic effects are
usually detected on the basis of retrospective information about the type and
intensity of the interventions that participants received prior to their response/nonresponse. However, in SMART designs, the interventions are manipulated
prospectively, with the type and intensity recorded during the trial.
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A SMART design also has the advantage of comparing multiple intervention
options at each single stage and within the context of what happens in later stages
while taking into account the delayed intervention effects. Specifically, a SMART
design can be used to study whether the effect of one intervention is enhanced by
subsequent or prior interventions. A SMART design can reduce deleterious cohort
effects(92-94) because participants who stay until the end of a SMART may be
more representative of the population than participants who remain in single-stage
trials. Many participants drop out of single-stage trials because the set of
interventions are fixed over time, which means that some participants will lack
beneficial treatment options and their adherence to the protocol will decrease. In
this sense, SMART is expected to be able to recruit participants who better
represent the relevant population as non-responders to the standard treatment are
more motivated to adhere to a trial that offers multiple and varying treatments and
are more receptive to the intervention(95).
Compared to a multi-arm trial with a fully formed intervention for each arm, the
SMART design enables us to understand the underlying mechanism of the
intervention by using randomized comparisons. In contrast, the multi-arm trial only
provides information on which arm is better. Building a multi-armed trial also
requires a lot of effort and information such as clinical experience, a variety of wellestablished theoretical principles and results from prior trials. A SMART design can
be used to identify useful patient-specific variables at each stage, which enables us
to address questions of clinical and theoretical interest such as whether the
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intervention provided to non-responding patients should differ depending on the
patient’s level of adherence to the initial intervention.
1.3.5 Scientific aims of SMART designs
In a SMART design, each stage corresponds to a critical decision point and
each individual many go through multiple stages. Participants are randomized one
or more times according to their response status. The randomization occurs at the
beginning of the intervention stages and is used to provide data for answering
scientific questions concerning intervention options at that stage. The goal of a
SMART is to inform the development of adaptive interventions. Three types of
scientific aims that can be addressed using a SMART are (1) the main effect aim,
which compares the overall effect for a treatment in a stage, (2) the embedded
adaptive interventions aim, which studies the interactive effect between the
intervention components between stages, and (3) the optimization aim, which finds
a more optimal sequence of treatments for each individual.
Specifically, the main effect aim addresses questions such as, “What is the
best initial treatment?” The answer to this question corresponds to the main effects
of the first-stage intervention options. Another question is, “What is the best
treatment option for non-responders?” Answering this question involves comparing
the interventions among non-responders, averaging over the duration of the initial
intervention, and corresponds to the main effect of the second-stage treatments.
This aim is useful for finding the efficacious adaptive intervention as it provides
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information, at each stage, on which intervention is more beneficial on average.
Statistical hypothesis tests are generally involved in this process.
The embedded adaptive intervention aim focuses on how treatment
components work with or against each other and determining the interactive effect
between them. It studies all the intervention groups embedded in the SMART. The
advantage of this aim is that the delayed effect can be captured when the long-term
effect of earlier stages appears in later stages. It seeks to identify the best
performing adaptive intervention rather than comparing two (or more) treatment
options alone.
The third aim, the optimization aim, is to propose an optimal intervention for an
individual based on a study of the patient-specific variables and tailored
interventions available in the SMART. Patient-specific variables that can inform
tailored interventions, other than those already embedded in the SMART, may be
identified during this process, which may lead to sequential treatment options that
are more specifically tailored to the individual patient and optimal interventions
beyond the existing adaptive interventions embedded in the SMART design.
Studies of this aim are very popular as it explores the potential for building a better
adaptive intervention for each individual. The optimization aim identifies baseline
variables that are useful for making decisions about the initial/first-stage treatment
as well as other intermediate variables, other than response status, that might be
useful in making decisions about the next treatment stage.
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The primary aim in a SMART can be one of the three scientific aims discussed
above. The choice depends on the scientific considerations specific to the area of
study and application. For example, in a smoking cessation study, the primary aim
is often to identify the most effective intervention at each stage, which can be
accompanied by the secondary aims of studying the quality of life and costeffectiveness associated with the interventions.
1.3.6 Designing a SMART
At each critical decision point in a SMART, all information available up to that
point can be viewed as the input of a certain systematic function for which the
output is the recommendation about the intervention for the following stage.
Specifically, participants in a SMART are assigned to their initial/first-stage
intervention(s) according to their individual baseline variables. Then, at the end of
the first stage, their response to the initial intervention, baseline variables and
intermediate variables obtained up to that point can be used to tailor the secondstage treatment options. This process can continue to the third and even further
stages while the intervention options can be further individualized by making use of
the heterogeneity within the participants. The design of the SMART should follow
the KISS principle(96): Keep it simple and straightforward at each intervention stage
and critical decision point. Summary statistics or measurements for each stage
should be low dimensional. Responder or adherence status is represented with
binary indicators. The designed SMART should be easy to apply in actual clinical
practice. And the treatment options in each stage should be restricted by feasibility
or certain scientific considerations. Additionally, in order to develop an adaptive
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intervention that is more specifically tailored to the individual patient, it is desirable
to use auxiliary time-varying measures and moderators. Choosing a simple primary
aim or primary aims in a SMART will aid the development of adaptive interventions
while powering the SMART to test this hypothesis. Appropriate steps are important
for developing a better SMART that can adapt to the needs of the individual
participant.
1.3.7 Analytical methods of SMARTs
Analytic methods and strategies for SMART designs depend on scientific
aims. Since there are typically two or more intervention stages in a SMART and the
outcomes of interest are measured after each stage, standard longitudinal data
analysis methods, such as linear mixed-effect models (LMM), can be used(97). In
addition, as the SMART design is also a type of factorial experimental design,
analytic methods for factorial experiments that were developed for behavioral
interventions can be applied. Specifically, the outcomes of participants from
different subgroups can be pooled to analyze the main effects of an intervention at
each stage by using a single indicator with levels that represent the types of main
effects.
If there are only two types of main effects to compare, the analysis is identical
to that used to analyze data arising from the RCT. A similar strategy can be applied
for an analysis associated with embedded adaptive interventions. However, unlike
the standard regression analyses to compare the main effects, a weighted-andreplicated regression approach is generally involved in this analysis as an
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adjustment to produce valid statistical results. The weights are used to
accommodate over- or under-representation of outcomes if the number of
randomizations are different or the randomization probabilities are not equal across
participants (for which the corresponding weights are inversely proportional to the
probability of being assigned a particular intervention sequence), or participants are
randomized to different numbers of intervention options(98-100). On the other hand,
replication is used for the application of standard software when observations for
participants are consistent with more than one embedded adaptive intervention.
Data analyses associated with the optimization aim can use the strategies
applied to standard moderator analysis for data arising from RCTs. Baseline
covariates can be included in the regression to help identify the effects of
interventions and explain for whom the intervention effects are stronger, which is a
typical approach used for RCT. Strategies for identifying useful variables to use in
building better adaptive interventions in a SMART are similar to those for
regressions with interactions between covariates and treatments, but with the focus
on exploring not only baseline variables but also intermediate variables. Various
types of machine learning strategies(101,102) can be applied for this type of
optimization analysis. Q-Learning(103) and A-learning(104,105) are two main
approaches for estimating the optimal treatment regime.
Q-learning uses backwards steps to construct a sequence of decision rules
that link the patient-specific variables and response status to past interventions to
the most efficient intervention option that can maximize the long-term primary
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outcome for each individual. Each step of Q-learning corresponds to an
optimization of the Q-function for that stage. Typically, the Q-function for each stage
of a SMART corresponds to a regression model, including all candidate patientspecific variables available up to that stage. The optimal intervention decision for
the current stage is then chosen by maximizing or minimizing the corresponding Qfunction, conditional on the fact that optimal adaptive decisions are achieved for all
subsequent stages. At the end of Q-learning analysis, an optimal adaptive
intervention that consists of the options for each stage is proposed. This adaptive
intervention can go beyond the existing adaptive interventions that are embedded in
the SMART. It is common in practice to use linear regression models for the Qfunctions, but they can be applied to complex relationships. There is a compromise
between choosing an interpretable and relatively simple model and mitigating the
risk of model misspecification through various approaches such as using flexible
models and support vector regression models(106).
As an alternative method to Q-learning, advantage learning(105) (i.e., Alearning) has been developed to identify the optimal regime without specifying the
Q-function. A-learning is either contrast-based or regret-based. In contrast-based
A-learning, contrast functions are specified and the g-estimation(107,108) method is
applied; whereas in regret-based A-learning, regret functions are implemented
using iterative minimization(108). A-learning relies on correct specification of the
contrast or regret functions to identify the optimal treatment regime. Although it also
involves the same recursive strategy as Q-learning, A-learning may be more robust
to model misspecification for consistently estimating the optimal treatment regime
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since models in A-learning are only posited for contrast and regret functions for the
part of the outcome regression. Nonetheless, Q-learning may be more efficient
relative to A-learning in parameter estimation when the Q-functions are correctly
specified. In addition, Q-learning may have practical advantages as it allows for the
use of standard modeling strategies and diagnostic tools; whereas A-learning may
be preferred in cases where the form of the decision rules defining the optimal
regime is not overly complex.
Other types of learning methods we introduce such as BOWL and SOWL(109)
are based on maximizing a nonparametric estimator of the expected long-term
outcome over all DTRs. In addition to these learning approaches, Zhang et al.(110)
proposed a robust estimation of the optimal DTR based on maximizing a doubly
robust augmented inverse probability weighted estimator for the population mean
outcome over a restricted class of regimes.
1.3.8 Sample size consideration of SMARTs
Although there are generally several subgroups at the end of a SMART, this
trial design does not require prohibitively large sample sizes because we are not
comparing the subgroups with covariance analysis. As the basic rule that the
minimum sample size for any experimental trial is determined by the primary aim for
that trial(111,112), consideration for the sample size of a SMART mainly depends
on its two primary aims: the main effect aim and the embedded adaptive
intervention aim. When comparing the two main effects of the first-stage
interventions in a SMART, data from all the subgroups that start with the same initial
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treatment are combined. Therefore, the sample size required for this effect is the
same as that for a two-group longitudinal RCT. Similarly, with the primary aim of the
second-stage intervention, subgroups with the same second-stage treatment are
combined for analysis. When considering the sample size and assuming the
embedded adaptive intervention aim as the primary aim, subgroups that constitute
an embedded adaptive intervention are compared to subgroups that constitute
another embedded adaptive intervention in the SMART.

1.4

Motivation and rationale of the studies in this thesis

1.4.1 Time-varying SMART design
In the modeling analysis of SMART, baseline characteristics and main and
interacting effects of the interventions at each stage are included as predictors for
the outcomes of interest, which are the dependent variables. Typically, the
treatment time of each stage in a SMART is fixed uniformly for all the participants.
In some two-stage SMART designs, the response is assessed at several pre-fixed
time points during the first stage. Once an assigned criterion is met, randomization
is conducted for that individual to the second stage. Examples of such SMART
designs are the study of the medication naltrexone for alcohol
dependence(80,113,114) and the study of pharmacological and behavioral
treatments for children with ADHD(76,80,113). Lu et al.(114) has recently
developed an analytic method for such SMARTs by using repeated-measures
piecewise marginal models.
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However, in such a time-fixed SMART design, subjects are assessed only at
fixed time points and thus the time of treatment only takes values along a finite set
of time points. Considering the cost and side-effects associated with treatments,
there are significant advantages to modifying or changing the current treatment
options as soon as an individual achieves an intermediate response. In SMART
designs, this strategy corresponds to re-randomization into the next stage, while
allowing for a varying duration of treatment among participants in the current stage.
Additionally, the time of each treatment is allowed to be a random variable that can
take any value on a subset of the positive real line and thus reflects the
corresponding treatment effect as an endogenous factor in the SMART. Specifically,
for a two-stage SMART, patients can be assigned to the second stage of treatment
as soon as his/her response during the first stage reaches a pre-specified goal. The
treatment time of the first stage is different among the patients while partially
suggesting the effect of the first-stage treatment. Such a time-varying SMART is
more efficient compared to the time-fixed SMART designs in terms of cost and sideeffects associated with the first-stage intervention. A modeling strategy that can
take advantage of the information about the first-stage treatment in addition to the
regression of the outcomes of interest is desirable for this type of time-varying
SMART. In this thesis, I developed the time-varying SMART design and proposed
the joint model for analyzing data obtained from such a design.
1.4.2 Bayesian randomization method for SMART
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Various randomization methods have been proposed and used in
experimental designs. With the development of multi-stage trials, allocation
strategies that make use of information accumulating during the trials, which fit into
the Bayesian framework, are applied. Response-adaptive randomization as
developed by Rosenberger and Lachin(115)adjusts the randomization probabilities
on the basis of the previous patients’ responses, with the goal of assigning more
patients to the superior treatment(s) as the trial progresses. Further development of
this approach was made by Karrison et al.(116), who proposed a group-sequential
response-adaptive design, Thall et al.(117), who developed an adaptive Bayesian
design, and Sverdlov et al.(118), who described multiple-objective responseadaptive designs. Rosenberger et al.(119) proposed a covariate-adjusted adaptive
allocation design and suggested a covariate-balanced allocation strategy to reduce
the bias induced from severe covariate imbalance across treatment arms. This
strategy was further developed by Signorini et al.(120), Heritier et al.(121) and
others. A combination of the two approaches has been applied by Ning and
Huang(122) and Yuan and Huang(123), in which the allocation method was
incorporated into a group-sequential randomization design. These methods assign
fewer patients to inferior treatment arms while controlling the imbalance of the
covariates across treatments when the sample size is moderate or small.
It is not straightforward to apply the above randomization strategies to the
SMART designs because participants are re-randomized in multiple stages and
embedded interventions are involved in such designs. Randomization in a SMART
considers optimizing the interventions for each participant. We can develop the
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corresponding allocation probabilities on the basis of certain optimization strategies.
The Q-learning algorithm provides parametric regression models that can be fitted
within the Bayesian framework and thus implies an allocation probability that favors
the optimal treatment options for each patient in a SMART. This probability for
optimal treatment assignment can be included with the response-adaptive and
covariate-balanced probabilities and then applied to the SMART design. In this
thesis, I developed a new allocation strategy for SMART, which extends the existing
response-adaptive and covariate-balanced randomization to multiple stages while
optimizing the individualized interventions for patients in a SMART.

1.5

Organization of the thesis
This dissertation discusses new designs and randomization methods for

SMART designs and shows their advantages in clinical research. The organization
of this thesis is as follows. Chapter 2 introduces our novel design of SMART. We
first review the design and analytic methods for the standard SMART on which our
new SMART design is based. Then we describe in details the proposed timevarying SMART and its corresponding data analysis methods. We show the
simulation approaches and results when comparing the proposed modeling
methods in chapter 2. We also compare the time-varying SMART with the standard
SMART with respect to the power for selecting the optimal intervention and the cost
associated with conducting the trials. Other related issues of the proposed design
are discussed in the last section of chapter 2.
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Chapter 3 describes a new randomization method for SMART. In the first
section, we review the existing allocation strategies in a clinical trial and propose the
new Bayesian randomization methods for SMART. Then we state the evaluation
and simulation approaches for comparing these new methods with other
randomization methods. We show the simulation results and discuss the advantage
of this proposed randomization method in the last two sections of this chapter.
Chapter 4 provides a conclusion and discussion of future work for the study of
SMART designs. The Appendix contains additional information and supplemental
tables and figures for Chapters 2 and 3
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Time-varying SMART Design and Data Analysis Methods for
Evaluating Adaptive Intervention Effects

(Most of the methods and results in this chapter have been published in BMC
Medical Research Methodology: Tianjiao Dai and Sanjay Shete, “Time-varying
SMART Design and Data Analysis Methods for Evaluating Adaptive
Intervention Effects”. The manuscript is currently available online BMC Med
Res Methodol. 2016 Aug 30;16(1):112. doi: 10.1186/s12874-016-0202-7.
According to the journal policy, the author retains the right to include the
published article in full or in part in a dissertation.)
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2.1

SMART designs and analysis

2.1.1 SMART designs
Sequential, multiple assignment, randomized trial (SMART) designs and their
analysis are being used to construct high-quality adaptive interventions that can be
individualized by repeatedly adjusting the intervention(s) over time on the basis of
individual progress(124-127). The SMART design was pioneered by Murphy,
building on the work of Lavori and Dawson(65,128). SMART designs involve an
initial randomization of individuals to different intervention options, followed by rerandomization of some or all of the individuals to another set of available
interventions at the second stage. At subsequent stages, the probability and type of
intervention to which individuals are re-randomized may depend on the information
collected from the previous stage (e.g., how well the patient responded to the
previous treatment; adherence to treatment protocol). Thus, there can be several
adaptive interventions embedded within each SMART design. This allows for testing
the tailored variables and the efficacy of the interventions in the same trial. There
are several practical examples of SMART studies that have been conducted (e.g.,
the CATIE trial(129) for antipsychotic medications in patients with schizophrenia,
STAR*D for the treatment of depression(125,130), and phase II trials at MD
Anderson for treating cancer(126)). The goal of these studies is to optimize the
long-term outcomes by incorporating the participant’s characteristics and
intermediate outcomes(131) evaluated during the intervention.
2.1.2 Standard SMART and analytic approaches
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An example of a two-stage SMART design is a study that characterized
cognition in nonverbal children with autism(127). To improve verbal capacity,
participants were initially randomized to receive either a combination of behavioral
interventions (Joint Attention Symbolic Play Engagement and Regulation (JASPER)
+ Enhanced Milieu Training (EMT)) or an augmented intervention (JASPER+EMT+
speech-generating device [SGD]). Children were assessed for early response
versus slow response to the first-stage treatment at the end of 12 weeks. The
second-stage interventions, administered for an additional 12 weeks, were chosen
on the basis of the response status (only slow responders to JASPER+EMT were
re-randomized to intensified JASPER+EMT or received the augmented
JASPER+EMT+SGD; slow responders to JASP+EMT+SGD received intensified
treatment; all early responders continued on the same intervention). There were
three pre-fixed assessment time points: at 12 weeks, 24 weeks and 36 weeks
(follow-up), which were the same for all participants in the study. Compared to
multiple, one-stage-at-a-time, randomized trials, SMART designs provide better
ability to compare the impact of a sequence of treatments, rather than examining
each piece individually. For example, a SMART allows us to detect possible
delayed effects in which an intervention at a previous stage has an effect that is less
likely to occur unless it is followed by a particular subsequent intervention option.
The typical modeling approach for the SMART design as described by NahumShani et al. includes the indicators of intervention at each stage as covariates and
thus accounts for the delayed effects on the final response. In order to develop a
sequence of best decision rules for each individual, various statistical learning
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methods of estimating the optimal dynamic treatment regimens have been
proposed, among which Q-learning has been developed for assessing the relative
quality of the intervention options and estimating the optimal (i.e., most effective)
sequence of decision rules with linear regression. For a two-stage SMART, the Qlearning approach controls for the optimal second-stage intervention option when
assessing the effect of the first-stage intervention, and reduces the potential bias
resulting from unmeasured causes of both the tailored variables and the primary
outcome. A similar approach for deriving the optimal decision rules for SMART is Alearning, which is more robust to model misspecification than Q-learning for
consistent estimation of the optimal treatment regime(105). Zhao et al. introduced
the two learning methods of BOWL and SOWL(109), which are based on directly
maximizing over all dynamic treatment regimens (DTRs) a nonparametric estimator
of the expected long-term outcome. As an alternative to the above learning
approaches, Zhang et al.(110) proposed a robust estimation of the optimal dynamic
treatment regimens for sequential treatment decisions, which maximizes a doubly
robust augmented inverse probability weighted estimator for the population mean
outcome over a restricted class of regimes. All these approaches model the
outcomes of interest as dependent variables, and for the predictor variables, they
model the main and interacting effects of the intervention options at each stage and
the baseline individual characteristics. The amount of time an intervention is
administered, however, is not explicitly modeled, although it can be used as a
covariate in these regressions.
2.1.3 SMART with multiple pre-fixed time point of evaluation
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There are examples of SMART designs in which a participant is assessed at
several pre-fixed time points during the first-stage treatment and once he/she meets
an assigned criterion for response status, he/she is re-randomized to the second
stage of treatment. Such a SMART design has been applied to develop a dynamic
treatment regime for individuals with alcohol dependence using the medication
naltrexone(80,113,114). At the beginning of the study, patients were randomized to
either a stringent or a lenient criterion for early non-response. Initially, all patients
received naltrexone. Starting at the end of the second week, patients who showed
early response were assessed weekly for eight weeks, and those who met the
assigned criterion for non-response were assigned to the second stage
randomization in that week; whereas the responders were re-randomized at week
eight. Another example of using a SMART design to evaluate multiple, fixed time
points is the study of pharmacological and behavioral treatments for children with
ADHD, where children were assessed monthly for response or nonresponse(80,124,132). In addition, Lu et al.(114) developed repeated-measures
piecewise marginal models for comparing embedded treatments in such SMART
designs with multiple evaluations at fixed time points. In these studies, subjects
were assessed at fixed time points; thus, the time of treatment takes values along a
finite set of time points.
2.1.4 Time-varying SMART designs
Although, SMART designs with outcome assessments at fixed time points
exist, there are advantages to administering a drug as soon as an individual
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achieves an intermediate response. For example, the smoking cessation drugs
varenicline and bupropion can increase the risk of psychological side effects such
as unusual changes in behavior, hostility, agitation, depressed mood and suicidal
thoughts(133-135). In addition, varenicline costs approximately $300 per month.
Therefore, allowing the duration of treatment to vary among participants for one or
more stages of the study may reduce the side effects and costs associated with the
interventions. For such time-varying SMART designs, the duration of treatment
plays an important role in decision making, and including it in the analysis may
increase the power of the study and better serve our goal of analysis. To further
extend the assignment strategies discussed in the above examples and utilize the
information contained in the treatment duration, in this paper, we proposed a novel
time-varying SMART design, which enables us to more efficiently assign different
intervention options as soon as an individual achieves a set of intermediate
response goals. Therefore, the time of treatment is a continuous random variable
for each individual that can take any value on a subset of the positive real line, and
is treated as an endogenous variable. The existing statistical methods are
inappropriate for analyzing data obtained from such a time-varying SMART design.
Therefore, to fully utilize the potential of this type of time-varying SMART design in
making more efficient decisions, we also proposed two analytic approaches that can
be used to analyze data from such a time-varying SMART design. The first
approach is a linear mixed model with time-varying fixed effects(136,137), which is
in fact a piecewise linear model. The second approach incorporates a joint modeling
method in which a survival model is fitted jointly with the linear mixed model(13835

140). We performed simulations to evaluate the statistical properties of both
methods. Our simulation results showed that both methods estimated the expected
final outcome for each embedded adaptive intervention in the design accurately, but
the joint-modeling method provided better estimates for certain parameters in the
model.
To compare the power and cost efficiency of the time-varying SMART design
to those of an analogous standard SMART design, we simulated two trials with
identical sample sizes and intervention effects using (a) the time-varying SMART
design and (b) the standard SMART design. These simulations showed that the
time-varying SMART design is cost-efficient and has power similar to that of the
standard SMART design in selecting the optimal embedded adaptive intervention.

2.2

Materials and Methods

2.2.1 Proposed Time-varying SMART Design
Figures 1 and 2 illustrate the proposed time-varying designs. Both two-stage
time-varying SMARTs were designed to provide data regarding how the intensity
and combination of two types of interventions might be adapted to a subject’s
progress in a cost- and time-efficient manner.
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Figure 1. Example of time-varying SMART design with equal probability
allocation: each participant is randomized twice

Figure 2. Example of time-varying SMART design with unequal probability
allocation: only non-responders are re-randomized in the second stage
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In the first example (see Figure 1), suppose medication (M) and behavioral
intervention (B) are two initial intervention options for individuals who are heavy
smokers (e.g., those who smoke more than or equal to 25 cigarettes per day). The
number of cigarettes a subject smokes per day is the outcome of interest and is
measured at the beginning of the study, at several intermediate time points and at
the end of the study. Let Y0 denote the number of cigarettes a subject smoked per
day at the beginning of the study (t=0). Subjects are randomly assigned to the
medication or the behavioral interventions at the beginning of the study. Monitoring
the outcome of interest begins at a pre-fixed time point (e.g. one week after the
initial randomization and is denoted as t00 ) after the initial intervention is
implemented, and t10 denotes the time point at which those who did not respond to a
first-stage intervention are re-randomized. A subject is considered a responder to
the first-stage intervention if there is a significant decrease in the number of
cigarettes the person smoked per day (e.g., the decrease in the number of
cigarettes smoked per day is above a pre-fixed threshold, C) at an intermediate time
point T1 , before t10 . Thus, T1 is a random variable of time and varies among
responders. A subject is classified as a non-responder if the decrease in the
number of cigarettes he or she smoked per day by t10 is below C. Therefore, all the
non-responders are given the first-stage intervention for a fixed time period of t10
(e.g., the first month of initial interventions), which can be seen as the rightcensored time point. Let Y1 denote the number of cigarettes smoked per day at the
end of the first-stage intervention.
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An indicator variable  is defined as   I (T1  t10 ) , where I () is the indicator
function that takes the value 1 if T1  t10 (i.e., if the subject is a responder) and the
value 0 if T1 ≥ t10 (i.e., if the subject is a non-responder). A responder is rerandomized either to continue with the first-stage intervention (M or B) or to receive
the first-stage intervention at a reduced intensity (M- or B-); whereas a nonresponder is re-randomized to receive the first-stage option at an increased
intensity (M+ or B+) or augmented with the other type of intervention (i.e., adding a
behavioral intervention for those who started with medication or adding medication
for those who started with a behavioral intervention). We let all the subjects in this
design stay on their second-stage interventions for a fixed time period, t (e.g., one
month). Therefore, for a subject whose first-stage intervention time is T1 , the total
study time is T1 + t , which we denote as T2 . For each participant, Y2 is the final
measurement of the number of cigarettes smoked per day at T2 ; see Figure 1).
The design illustrated in Figure 2 is similar to that in Figure 1 except that all
the responders continue with their first-stage intervention options (i.e., each
responder receives the same intervention after the response time point T1 ) (see
Figure 2).
The adaptive interventions that are embedded within the two SMART designs
in Figures 1 and 2 are listed in Appendix: Tables S1 and S2.
2.2.2 Analytic approaches
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Let A1 and A2 be the indicators of the first- and second-stage intervention
options, respectively. For each individual, we observe the data

(Y0 , A1 , T1 , Y1 , A2 , Y2 , T2 ,  ) . The outcomes of interest are the longitudinal measurements
Y0 , Y1 , and Y2 , which are fitted with a linear mixed model, assuming they share the
same random intercepts at the subject level. Because the intervention options and
their durations change over time in this design, we first proposed a straightforward
time-varying mixed effects model (TVMEM) to analyze the outcomes. In this
approach, the duration of time a treatment is administered is used as a covariate in
the model. Such an approach is better than the approaches that ignore the time
component of the intervention (i.e., the duration of the intervention influences its
effect). However, the time duration is a random variable and one may gain
statistical efficiency by treating it as a random variable in the modeling. Therefore,
we also proposed a joint-modeling approach that simultaneously postulates a linear
mixed effects model for the longitudinal measurements Y  (Y0 , Y1 , Y2 ) and a Cox
model for the survival time T1 . In particular, we fit a survival submodel for T1 jointly
with the previously mentioned TVMEM that will efficiently extract the information
contained in T1 .
2.2.2.1 Time-varying mixed effects model of Y  (Y0 , Y1 , Y2 )
A linear TVMEM is fitted to the longitudinal outcomes, with interventions and
their interactions and durations included as predictors. For each individual i in the
study, we have
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Yi (t )  mi (t )   i (t )  Zi  (t )  Xi (t )  (t )  bi   i (t)
 Zi  (t )  0 (t )  1 (t ) A1i (t )  2 (t ) A2i (t )  3 (t )t  4 (t ) A1i (t )  A2i (t )  bi   i (t)

(1),

where mi (t ) is the unobserved true value of the longitudinal outcome at time point t,
and bi is the subject-level random effects and is assumed to be normally distributed
with a mean of zero and variance of  b2 ; Zi is a vector of the baseline covariates (e.g.,
age, sex, comorbidities, etc.) with a corresponding vector of the regression
coefficients  (t ) ; X i (t ) is the vector of the first-stage and second-stage intervention
options, their interactions, and duration of intervention with a corresponding vector
of the regression coefficients  (t ) . Finally,  i (t ) is the error term at time t and is
assumed to be normally distributed and independent of bi .
In our study design, we consider three time points at which the outcomes of
interest are measured: t = 0, T1i and T2i , where T1i and T2i are the respective time
points at which individual i completes the first- and second-stage interventions.
Therefore, A1i (t ) takes the value of A1i at times T1i and T2i and is equal to 0 at t  0 ,
and A2i (t ) takes the value of A2i at T2i and is equal to 0 at time points 0, and T1i . In
this way,  (t ) and  (t ) are piecewise linear fixed coefficients; therefore, model (1) at
the three time points is equivalent to the following three linear mixed-effects
submodels:

Y0i  Yi (0)  mi (0)   i (0)
 Zi  (0)  XTi (0)  (0)  bi   i (0)
 Zi 0  00  bi   0i

(2),
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Y1i  Yi (T1i )  mi (T1i )   i (T1i )
 Zi  (T1i )  XTi (T1i )  (T1i )  bi   i (T1i )
 Zi 1  01  11 A1i  31T1i  bi  1i

(3)

and
Y2i  Yi (T2i )  mi (T2i )   i (T2 i )
 Z i  (T2i )  XTi (T2 i )  (T2 i )  bi   i (T2 i )
 Z i 2   02  12 A1i   2 A2i   32T2i   4 A1i  A2i  bi   2i
 Z i 2   02  12 A1i   22 A2 Ri   23 A2 NRi   32T2i   41 A1i  A2Ri   42 A1i  A2NRi  bi   2i

(4) ,

where in equations (2) through (4), Y0i , Y1i and Y2i are the outcome values at time 0,

T1i and T2i , respectively; A1i is the indicator of the first-stage intervention options (-1
for M and +1 for B), A2i  ( A2 Ri , A2 NRi ) is the indicator vector for the second-stage
intervention options, where A2Ri is the indicator for the second-stage intervention
options for the responders to the first-stage intervention (1=continue the initial
intervention; −1= reduce the intensity of the initial intervention) and A2 NRi is the
indicator for the second-stage intervention options for the non-responders
(1=increase the initial intervention; −1= augment the initial intervention with the
other type of intervention), with A2Ri =0 for non-responders and A2 NRi =0 for
responders. A1i  A2 Ri and A1i  A2 NRi are the interaction effects of the first-stage
intervention and second-stage intervention among responders and non-responders,
respectively, in the submodel of Y2i (i.e., submodel (4)). Models (1) - (4) can also be
written in the form of conditional expectation as shown in supplementary information
1.1 in Appendix.
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Parameters 0 ,1 ,2 and 00 , 01 , 02 are the coefficients of the baseline
covariates and intercepts at time points 0, T1i and T2i , respectively; submodel (2)
includes only baseline covariates as predictors for the outcomes at the beginning of
the study (i.e., Y0i at t=0); submodel (3) models the outcome of interest at the
intermediate time point of the study (i.e., Y1i at t= T1i ) and includes covariates A1i and

T1i , for which the corresponding coefficients 11 and  31 account for the direct
effect of A1i and indirect effects through T1i on Y1i ; submodel (4) includes all the
main and interacting effects of the intervention options at each stage and the
duration T2i ( T2i  T1i  t ) as predictors, for which the coefficients 12 and  32
account for the delayed effect of A1i and delayed indirect effects of A1i through T2i .
The coefficients  2  (  22 ,  23 ) and  4  (  41 ,  42 ) account for the effects of the
second-stage interventions and the effects of their interactions with the first-stage
interventions on the final outcome Y2i (measured at the end of the study, T2i ).
In appendix, we also provided conditional expectations of the final outcomes
for each of the 8 embedded adaptive interventions in the SMART design of Figure 1
in supplementary information 1.2 and four embedded adaptive interventions in the
SMART design of Figure 2 in supplementary information 1.3.
2.2.2.2 Joint model
In addition to the TVMEM, we postulate a relative risk model for T1i (time to the
event of interest) as
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h i (t )  h 0 (t ) exp{ 1 A1i   2Wi   mi (0)},

(5)

where Wi is a vector of the baseline covariates, which could be different from vector

Zi in model (1) , and h 0 () is the baseline risk function. The underlying longitudinal
measurement mi (0) at baseline (i.e., at time point t=0), as approximated by the
TVMEM, and at the first-stage intervention A1i are included as predictors in model
(5) because the time point at which an individual responds to the first-stage
intervention (i.e., T1i ) depends only on the type of first-stage intervention the subject
received and the baseline covariates.
We jointly estimate the coefficients in models (1) and (5) by using the
maximum likelihood estimation method. To define the joint distribution of the timeto-event and longitudinal outcomes, we assume that the random effect bi underlies
both the longitudinal and survival processes for each subject. This means that the
random effect accounts for both the association between the longitudinal and event
outcomes and the correlation between the repeated measurements in the
longitudinal process. We also assume that the longitudinal outcomes Y0i , Y1i , Y2i 
are independent of the time T1i conditional on the random effect bi . Therefore, the
joint likelihood contribution for the ith subject can be formulated as p(T 1i ,  i , Yi ; ) 

 p(T

1i

,  i | bi ;  ,  ,  , )[ p{Yi (t ij ) | bi ;  ,}]p(b i ;  b ) db , where p{Yi (t ij ) | bi ;  ,} is the
j

univariate normal density for the longitudinal responses at time point t ij , which is the
element from the vector t i  {t si }2s 0  {0, T1i , T2i } ; p(bi ; b ) is the normal density with
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standard deviation  b for the random effects bi ; and p(T 1i ,  i | bi ;  ,  ,  , ) is the
likelihood for the time to the intermediate outcome and can be written as

p(T 1i ,  i | bi ;  ,  ,  , ) = {h i (T1i | mi (0);  ,  ,  , )}i  Si (T1i | mi (0), A1i ;  ,  ,  , ) =
T1i

{h i (T1i | mi (0);  ,  ,  , )}i  exp{ h i (s | mi (0);  ,  ,  , ) ds} , where  i  I (T1i  t10 ) .
0

Parameters in the model are estimated by maximizing the corresponding loglikelihood function with respect to (  ,  ,  , ) . We obtained the maximum likelihood
estimates using the R package “JM”(141,142).
The parameters ( 12 , 22 , 23 , 32 , 41 , 42 ) in submodel (4) (i.e., the model of
final outcome Y2 ) are of primary interest and were estimated using the two
approaches described above.
The data organization and implementation of these methods are presented in
supplementary information 2 and 3 in Appendix.

2.3

Simulations

2.3.1 Simulation approach 1
For the example illustrated in Figure 1, we considered two simulation
scenarios in which Y0 and Y1 were simulated using submodels (2) and (3),
respectively, and Y2 was simulated with and without the interaction terms ( A1i  A2 Ri
and A1i  A2 NRi ) in submodel (4). In both scenarios, we simulated 500 replicates of
n=1000 individuals, and randomly assigned subjects (with probability 0.5) to one of
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the two first-stage interventions (i.e., A1 to be equal to 1 [behavioral intervention] or 1 [medication]). Responders and non-responders to the initial interventions were
then re-randomized (with probability .5) to one of the corresponding second-stage
intervention options (i.e., A2 R and A2NR were randomly assigned to be 1 or -1 and

A2 R =0 for non-responders and A2NR =0 for responders; see Figure 1). In both
scenarios, the random effects {bi }in1 for subjects i  1, 2,..., n were generated from
the normal distribution with a mean of 0 and a standard deviation of 5, and baseline
outcomes {Y0i }in1 were simulated using submodel (2) with parameters  00  10 and

 2i ~ N (0, 42 ) . The intermediate outcomes {Y1i }in1 were simulated using submodel (3)
with parameters  01  1 , 11  0.2 , and 31  0.1 in the first scenario; whereas
outcomes {Y1i }in1 in the second scenario were simulated with  01  1, 11  0.6 , and

31  0.1, with a standard deviation of 5 ( i.e., 1i ~ N (0,52 ) in both scenarios and
satisfying the conditions Y0i  Y1i  9 (C=9) if subject i is a responder and Y0i  Y1i  9
if subject i (i  1, 2,...n) is a non-responder.
The time points T1i were generated from a left-truncated Weibull distribution
(truncated from t00 =0.1, the start time for monitoring), with shape=1 and scale=

exp{ 0   1 A1i   mi (0)} , where  0  1.5 ,  1  0.4 , and   0.25 , and those for
whom T1i was greater than 1 (non-responders), were assigned T1i  t10  1 (the
maximum time the first-stage intervention is administered [t10]). The indicator of
response status was then defined by  i  I (T1i  1) .The final outcomes Y2i (i  1,..., n)
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were generated using submodel (4), with  2i ~ N (0,52 ) . The values of the other
parameters in submodel (4) are reported in Table 1 (without interactions) and Table
2 (with interactions).
For the intervention strategy depicted in Figure 1, there are eight adaptive
interventions imbedded in the design and represented by the three indicators A1 , A2 R ,
and A2NR . For example, in adaptive intervention ( A1 , A2 R , A2 NR ) = (-1, 1, 1),
participants are initially randomized to the medication ( A1  1 ); those who respond
are re-randomized to continue on the medication ( A2 R  1 ) and those who do not
respond are re-randomized to increased medication ( A2 NR  1). Another example of
an adaptive intervention is ( A1 , A2 R , A2 NR ) = (1, 1, -1), in which participants are initially
randomized to a behavioral intervention ( A1  1 ); those who respond are rerandomized to continue on the behavioral intervention ( A2 R  1 ), and those who do
not respond are re-randomized to an augmented arm (M+B, A2 NR  1 ).
For the design in Figure 2, only the non-responders are re-randomized in the
second stage. Therefore, there are four embedded adaptive interventions in this
design, which are represented by the vector of two indicators ( A1 , A2 NR ). For
example (-1,-1) represents the adaptive intervention in which participants are
initially randomized to medication ( A1  1 ) and those who do not respond are rerandomized to the augmented arm (M+B, A2 NR  1 ), whereas responders continue
on the medication arm.
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Using this design, we also simulated the treatment of 1000 subjects. However,
instead of using equal probability allocations as in Figure 1, we used unequal
probability allocations at both stages. Specifically, each of the 1000 subjects were
initially assigned to either A1 =-1 (medication) or A1 =1 (behavioral intervention) with
probabilities 0.4 and 0.6, respectively. Then, the non-responders were re-allocated
into either A2NR =-1 (augmented first-stage intervention, M+B) or A2NR =1 (intensified
first-stage intervention, M+ or B+) with probabilities 0.55 and 0.45, respectively;
whereas all responders were continued on their initial interventions (therefore, A2 R
=0). Random effects ( bi ), errors (  i ), and longitudinal outcomes ( Y0i , Y1i (i  1,..., n) )
were generated as described for Figure 1. The final outcomes, Y2i (i  1,..., n) , were
also generated using submodel (4), but without the variable A2Ri , with the parameter
values reported in Tables 3 and 4 for the two scenarios, respectively. In the first
scenario, outcomes Y2i (i  1,..., n) were simulated without interaction terms and with
the parameter values shown in Table 3; in the second scenario, outcomes

Y2i (i  1,..., n) were simulated with interaction terms and with the parameter values
shown in Table 4.
2.3.2 Simulation approach 2
For the design illustrated in Figure 1, we performed an alternate simulation
approach that does not simulate values for T1i from the Weibull distribution. Instead,
we considered a situation in which values of Y1i are monitored and T1i is the value
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for which the Y1i crosses the pre-specified boundary condition for the first time. In
this simulation approach, random effects {bi }in1 and error terms  0 , 1 and  2 were all
simulated the same way as described above. Baseline outcomes {Y0i }in1  1 are
simulated using submodel (2) with 00  2 and  0i ~ N (0, 22 ) . Furthermore, we
defined an individual i , as a responder if he/she had a certain percentage reduction
in the intermediate outcome value, Y1i , compared to his/her base-line value Y0i . This
may be a more appropriate definition of responders in some practical scenarios
than a simple reduction by a fixed amount (e.g., C = 9) as was used in the previous
simulations. In this simulation, those with a 40% reduction from their baseline
values were considered responders. The parameter values used for submodel (3)
were 01  2 , 11  0.5 , and 31  5 . For an individual i , we first simulated

1i ~ N (0, 22 ) and calculated T1i* for which the 01  11 A1i  31T1i*  bi  1i equals the
40% reduction from Y0i , the baseline value. Therefore, we define T1i  t00 , if T1*i  t00 ;
T1i  T1*i , if t00  T1*i  t10 ; and T1i  t10 , if T1*i  t10 . Then, T1i is substituted in the right

side of equation (3) to obtain the value of Y1i for the individual i ( i  1,..., n) The final
outcomes Y2i (i  1,..., n) were generated using submodel (4), with  2i ~ N (0, 22 ) . As
previously, we simulated 500 replicates of n =1000 individuals in each trial, and
randomly assigned subjects (with probability 0.5) to one of the two first-stage
interventions (i.e., A1 to be equal to 1 [behavioral intervention] or −1 [medication]).
Responders and non-responders to the initial interventions were then rerandomized (with probability 0.5) to one of the corresponding second-stage
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intervention options (i.e., A2 R and A2NR were randomly assigned to be 1 or −1 and

A2 R  0 for non-responders and A2 NR  0 for responders; see Figure 1.).
We evaluated the performance of our two proposed analytic approaches in
these simulated data sets by measuring the (a) means of the estimates of each of
the adaptive interventions embedded in the design, (b) parameter estimates in the
model, (c) mean squared error (MSE), (d) estimated coverage probability of the
95% confidence interval, and (e) length of the confidence interval.
Using these simulations parameters, we simulated two trials with identical
sample sizes: (a) the time-varying SMART design and (b) the standard SMART
design. We evaluated the performance of the time-varying SMART design and an
analogous standard SMART design by measuring the (a) power to select the
optimal embedded intervention, and (b) associated cost.

2.4

Results
Tables 1-4 show the results of the two simulation scenarios based on the

design shown in Figure 1. Similarly, Tables 5-8 show the results of the two
simulation scenarios for the design in Figure 2.
In Table 1 the true parameters were the coefficient of the first-stage
interventions, 12  0.4 ; coefficient of the second-stage intervention for responders,

22  0.5 ; coefficient of the second-stage intervention for non-responders, 23  0.5 ;
and coefficient of T2, the total time of the first- and second-stage interventions,

32  2 . The estimates obtained using TVMEM were 𝛽̂12  0.275, 𝛽̂22  0.503, 𝛽̂23
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 0.501, and 𝛽̂32  4.073 , while the estimates obtained using the joint model were

β̃12  0.407, β̃22  0.503, β̃23  0.502, and β̃32  1.790 . Both approaches estimated
coefficients  22 and  23 accurately. The parameters 12 and  32 were estimated
accurately using the joint model, but poorly using the TVMEM. Similarly, in terms of
the MSE, the length of the 95% confidence interval, and the estimated coverage
probability of the 95% confidence interval, both approaches performed similarly for
estimating  22 and  23 , but joint modeling performed better for estimating 12 and

32 . For example, for 12 , the estimated coverage probability obtained using the
TVMEM was 88%; whereas that obtained from the joint model was 97.8%. For each
of the eight embedded adaptive interventions in the design, Table 2 shows that both
approaches accurately estimated the means of the final outcome, E[Y2 | ( A1 , A2 R ,

A2 NR )] . For example, the simulated means of the adaptive interventions
( A1 , A2 R , A2 NR ) = (-1, -1, - 1), (-1, 1, 1), and (1, 1, 1) were 4.538, 5.536, and 6.564,
respectively, and the estimated means were 4.543, 5.531, and 6.569, respectively,
using both the TVMEM and joint model.
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Table 1. Simulation results for the design in Figure 1.: the estimated means, based
on 500 replicates, are reported for coefficients in model (4)
Parameter estimation
β12
(first-stage
interventionsA1)

True
value

Joint
Model

TVME
M

β22

β23

(second-stage
interventions
for responders A2R)

β32

(second-stage interventions

(time of

for non-responders A2NR)

intervention T2)

0.4

0.5

0.5

2

Estimate

0.407

0.503

0.502

1.790

MSE

0.011

0.029

0.016

0.147

CI%

97.8%

95.0%

96.8%

94.2%

Length of
CI

0.478

0.674

0.538

1.447

Estimate

0.275

0.503

0.501

4.073

MSE

0.026

0.030

0.017

4.400

CI%

88.0%

95.6%

97.0%

0.0%

Length of
CI

0.484

0.695

0.549

1.436

CI%: Coverage probability of the 95 % confidence interval
MSE mean squared error

Table 2. Simulation results for the design in Figure 1.: the estimated means, based
on 500 replicates, are reported for the final outcomes of the eight adaptive
interventions embedded in the design
Mean of the final outcomes

Simulated
means
Estimated
means by
Joint
model
Estimated
means by
TVMEM

(−1,-1,-1)

(−1,-1,1)

(1,-1,-1) (1,-1,1) (−1,1,-1) (−1,1,1) (1,1,-1)

4.538

5.087

5.554

6.275

4.988

5.536

5.842

6.564

4.543

5.093

5.549

6.269

4.982

5.531

5.849

6.569

4.543

5.093

5.549

6.269

4.982

5.531

5.849

6.569
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(1,1,1)

Tables 3 and 4 show results similar to those in Tables 1 and 2, respectively. In
Table 3, the coefficient of interaction of the first-stage interventions and secondstage interventions among responders is denoted by  41 , and the coefficient of
interaction of the first-stage interventions and second-stage interventions among
non-responders is denoted by  42 . As shown in Table 3, both TVMEM and joint
modeling accurately estimated parameters  22 ,  23 ,  41 , and  42 , with little difference
in the MSE, estimated coverage probability, and length of the 95% confidence
interval. However, as in Table 1, the joint modeling approach estimated 12 and  32
more accurately than the TVMEM approach. For example, the true coefficient of T2
was 32  2.0 , which was poorly estimated as 4.122 using the TVMEM and
estimated as 1.626 using the joint model. Table 4 shows that the estimated means
of the eight adaptive interventions obtained from both analytical approaches were
identical and close to the simulated means up to the third decimal.
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Table 3. Simulation results for the design in Figure 1: the estimated means, based
on 500 replicates, are reported for coefficients in model (4) with interactions
Parameter estimation
β12

β22

interventionsA1)

Joint
model

TVME
M

β32

β41

β42

interventions

(time of

(interaction

(interaction

for non-

intervention T2)

term A1. A2R)

term A1. A2NR)

(second-stage

(second-stage

(first-stage

True
value

β23

interventions
for responders A2R)

responders A2NR)

−0.4

0.5

0.4

2.0

0.55

−0.40

Estimate

−0.381

0.490

0.389

1.626

0.542

−0.397

MSE

0.014

0.038

0.019

0.305

0.037

0.019

CI%

97.4%

95.6%

96.8%

87.0%

96.8%

98.0%

Length
of CI

0.521

0.789

0.593

1.671

0.789

0.593

Estimate

−0.530

0.489

0.390

4.122

0.542

−0.396

MSE

0.029

0.039

0.020

4.697

0.037

0.020

CI%

88.2%

95.8%

96.4%

0.0%

97.0%

97.8%

Length
of CI

0.525

0.809

0.605

1.618

0.809

0.605

CI%: Coverage probability of the 95 % confidence interval
MSE mean squared error

Table 4. Simulation results for the design in Figure 1: the estimated means, based
on 500 replicates, are reported for the final outcomes of the eight adaptive
interventions embedded in the design with interactions in model (4)
Mean of the final outcomes

Simulated
means
Estimated
means by
Joint model
Estimated
means by
TVMEM

(−1,-1,-1)

(−1,-1,1)

(1,-1,-1) (1,-1,1) (−1,1,-1) (−1,1,1) (1,1,-1)

5.456

6.306

5.009

5.000

5.400

6.249

5.577

5.565

5.456

6.306

5.009

5.000

5.400

6.249

5.577

5.565

5.456

6.306

5.009

5.000

5.400

6.249

5.577

5.565
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(1,1,1)

Similar trends were observed in Tables 5-8 for the two simulations of Figure 2.

12 and 32 were better estimated using the joint modeling approach, whereas all
the other parameters and the means of the final outcomes of the four adaptive
interventions embedded in the design were accurately estimated using both
approaches.
In Table 5, the true coefficient values of 12 =0.450 and  32 =2.0 were estimated
as𝛽̂12 =0.388 and𝛽̂32 =4.046 using the TVMEM, and as 12 =0.456 and β̃32 =1.767
using the joint model. Coefficient  23 was accurately estimated using both models.
As for the four adaptive interventions (i.e. ( A1 , A2 NR )= (-1,1), (-1,-1), (1, 1) and (1, -1))
embedded in the design of Figure 2, Table 6 shows that the simulated means were
5.213, 4.802, 6.330, and 5.805, respectively, and the estimated means were 5.228,
4.790, 6.344, and 5.793, respectively, using the TVMEM, and 5.230, 4.788, 6.345,
and 5.792, respectively, using the joint model.
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Table 5. Simulation results for the design in Figure 2: the estimated means, based
on 500 replicates, are reported for coefficients in model (4)
Parameter estimation
β12

β23
(second-stage

(first-stage
interventions A1)

True

β32
(time of

interventions for

intervention T2)

non-responders A2NR)

0.450

0.40

2.0

Estimate

0.456

0.441

1.767

Joint

MSE

0.013

0.017

0.168

model

CI%

95.6%

95.6%

93.6%

Length of CI

0.482

0.536

1.452

Estimate

0.388

0.439

4.046

MSE

0.016

0.017

4.297

CI%

94.0%

96.0%

0.0%

Length of CI

0.489

0.547

1.442

value

TVMEM

CI%: Coverage probability of the 95 % confidence interval
MSE mean squared error

Table 6. Simulation results for the design in Figure 2: the estimated means, based
on 500 replicates, are reported for the final outcomes of the four adaptive
interventions embedded in the design
Mean of the final outcomes

Simulated means

(−1,1)

(−1,-1)

(1,1)

(1,-1)

5.213

4.802

6.330

5.805

5.230

4.788

6.345

5.792

5.228

4.790

6.344

5.793

Estimated means by
joint model
Estimated means by
TVMEM

Table 7 shows that the true parameters 12 =0.40 and  32 =2.0 were
respectively estimated as 𝛽̂12=0.298 and 𝛽̂32 =4.308 using the TVMEM, and as
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β̃12=0.408 and β̃32 =1.784 using the joint model. The other two parameters,  23 and

 42 , were accurately estimated using both approaches. Table 8 shows that the
means were accurately estimated using both approaches.
Tables 9 and 10 show the results from the alternative simulation strategy. In
Table 9 the true coefficient values of 12 = −0.6 and  32 = −1.5 were estimated as
𝛽̂12= −0.534 and 𝛽̂32= −2.367 using the TVMEM, and as β̃12= −0.608 and β̃32 =
−1.338 using the joint model. Coefficients  22 ,  23 and the means of the final
outcomes of the eight adaptive interventions embedded in the design were
accurately estimated using both approaches (Table 10).
Table 7. Simulation results for the design in Figure 2: the estimated means, based
on 500 replicates, are reported for coefficients in model (4) with interactions
Parameter estimation
β12

β23

β32

β42

(second-stage
(first-stage

interventions

(time of

(interaction

intervention A1)

for responder

intervention T2)

termA1 A2NR))

A2NR)

0.4

0.4

2.0

−0.4

Estimate

0.408

0.422

1.784

−0.400

Joint

MSE

0.012

0.020

0.157

0.019

model

CI%

98.2 %

97.2 %

95.6 %

97.2 %

Length of CI

0.513

0.594

1.542

0.593

Estimate

0.298

0.419

4.308

−0.399

MSE

0.021

0.021

5.439

0.020

CI%

94.8 %

97.4 %

0.0 %

97.4 %

Length of CI

0.520

0.608

1.532

0.607

True value

TVMEM

CI%: Coverage probability of the 95 % confidence interval;
MSE: mean squared error
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Table 8. Simulation results for the design in Figure 2: the estimated means, based
on 500 replicates, are reported for the final outcomes of the four adaptive
interventions embedded in the design with interactions in model (4)
Mean of the final outcomes

Simulated means

(−1,1)

(−1,-1)

(1,1)

(1,-1)

5.487

4.622

6.032

6.059

5.502

4.610

6.047

6.046

5.500

4.611

6.045

6.048

Estimated means by
joint model
Estimated means by
TVMEM

Table 9. Simulation results from the alternative simulation approach: the estimated
means, based on 500 replicates, are reported for coefficients in model (4)
Parameter estimation
β12

β23

β32

β42

(first-stage

(second-stage

(time of

(interaction

intervention A1)

interventions

intervention T2)

term A1 . A2NR)

for responder A2NR)

True
value

Joint
model

TVMEM

−0.6

0.5

0.4

−1.5

Estimate

−0.608

0.492

0.447

−1.338

MSE

0.002

0.003

0.018

0.034

CI%

97 %

96 %

87 %

70 %

Length of CI

0.199

0.192

0.376

0.411

Estimate

−0.534

0.492

0.448

−2.367

MSE

0.007

0.003

0.020

0.763

CI%

74 %

93 %

84 %

0%

Length of CI

0.197

0.191

0.376

0.529

CI%: Coverage probability of the 95 % confidence interval
MSE mean squared error
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Table 10. Simulation results from the alternative simulation approach: the estimated
means, based on 500 replicates, are reported for the final outcomes of the eight
adaptive interventions embedded in the design
Mean of the final outcomes
(−1,-1,-1) (−1,-1,1) (1,-1,-1) (1,-1,1) (−1,1,-1) (−1,1,1) (1,1,-1)

(1,1,1)

Simulated means

−0.208

−0.070

−1.589 −1.356

0.678

0.810

−0.918 −0.689

Estimated means
by Joint model
Estimated means
by TVMEM

−0.203

−0.066

−1.595 −1.359

0.675

0.804

−0.915 −0.683

−0.203

−0.063

−1.594 −1.363

0.672

0.804

−0.912 −0.684

2.5

Comparison of power between the time-varying SMART design and the
standard SMART design
We analyzed the time-varying SMART design’s ability to select the most

optimal embedded intervention and compared the associated power to that of the
standard SMART design. We performed the comparison by conducing two trials
with identical sample sizes and intervention effects using (a) the time-varying
SMART design and (b) the standard SMART design. Figure 3 represents the
standard SMART design that is analogous to the time-varying SMART design
depicted in Figure 1. The major difference between the two designs is that in the
time-varying SMART design, a responder is re-randomized to the second-stage
intervention at a random response time T1 (< t10 ); whereas in the standard SMART
design, everyone is re-randomized at a fixed time point t10 . Responders are defined
similarly in both designs. In our example, a subject is considered a responder to the
first-stage intervention if there is a significant decrease in the number of cigarettes
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the person smoked per day. The second-stage intervention is identical for both
designs.

Figure 3.Example of standard SMART design with equal probability allocation:
each participant is randomized twice

For both designs, we calculated the percentage of times the best embedded
intervention is selected (i.e., the power of the design). We simulated six parameter
scenarios: the true parameters for the coefficient of the first-stage interventions,

 21 ; coefficient of the second-stage intervention for responders,  22 ; coefficient of
the second-stage intervention for non-responders,  23 ; coefficient of T2 , the total
time of the first- and second-stage interventions,  32 ; coefficient of interaction of the
first-stage interventions and second-stage interventions among responders  41 ; and
the coefficient of interaction of the first-stage interventions and second-stage
interventions among non-responders  42 . The simulated values of each of these
parameters are reported in Tables 11 and 12. The simulation results are based on
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500 replicates and are shown in Table 11 for comparing the two designs in Figure1
(time-varying SMART) and Figure 3 (analogous standard SMART). Overall, both
designs were equally effective in selecting the optimal embedded adaptive
intervention. For example, when 21  0.4 , 22  0.5 , 23  0.5 and 32  2 , using
the joint model and implementing the time-varying SMART design showed 82.8%
power to select the optimal embedded adaptive intervention; whereas the power
associated with the standard SMART design was 83.0%. Similar results were
obtained when comparing the time-varying SMART design in Figure 2 and the
standard SMART design in Figure 4 (see Table 12).

Table 11. Power to select the optimal embedded adaptive intervention strategy for
designs in Figures 1 and 3.
Comparison
of designs in
Figures 1
and 3.

Without
interaction

With
interaction

12

 22

 23

32

 41

 42

Power to select optimal
embedded adaptive
strategy
Time-Varying
SMART

Standard
SMART

0.4

0.5

0.5

2

82.8%

83.0%

0.3

-0.2

0.4

2

60.2%

59.2%

0.3

-0.5

0.4

2

76.2%

75.0%

0.4

0.5

0.5

2

0.5

-0.3

99.2%

97.0%

0.6

0.5

0.4

2

0.2

0.2

63.0%

62.8%

0.6

-0.5

-0.5

2

0.2

-0.3

72.2%

73.4%
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Figure 4. Example of standard SMART design: only non-responders are rerandomized in the second stage

Table 12. Power to select the optimal embedded adaptive intervention strategy for
designs in Figures 2 and 4
Comparison of
designs in
Figures 2 and 4.

Without
interaction

With interaction

12

 23

32

 42

Power to select optimal
embedded adaptive strategy
Time-Varying
SMART

Standard
SMART

0.5

0.5

2

92.8%

90.6%

0.45

0.4

2

86.6%

83.6%

-0.2

0.2

2

68.4%

66.2%

0.4

0.4

2

-0.4

98.2%

97.4%

0.2

0.2

2

-0.4

88.4%

87.6%

0.4

0.1

2

-0.25

77.4%

78.6%
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2.6

Comparison of the cost associated with conducting the time-varying
SMART design versus that associated with conducting the standard
SMART design
To assess the cost associated with the conducting trials using these two

competing designs, we considered a linear cost function for both SMART designs.
Let c1 and c2 be the cost of the medication (M) and behavioral intervention (B),
respectively. Additionally, we assumed that the reduced and increased intensity of
the first-stage intervention are at half and twice the cost of the first-stage
intervention, respectively, and that augmentation of the first-stage intervention in the
second stage (M+B) has the cost c1  c2 . Using these parameters, the cost for the
time-varying SMART design in Figure 1 is

cos t  c1 (

c
t)  ( 1 )(  t)  (2c1 )(  t) 
2 A2 i =M 
A2 i =M
A2 i =M 

 T )c ( 
1i

A1i  M

1

c
c2 (  T1i )  c2 (  t)  ( 2 )(  t)  (2c2 )(  t)  (c1  c2 )(  t),
2 A2 i =B 
A1i  B
A2 i =B
A2 i =B 
A2 i =M  B
and the cost for the corresponding standard SMART in Figure 3 is

cos t  c1 (

t

A1i  M

10

)  c1 (

c
t)  ( 1 )(  t)  (2c1 )(  t) 
2 A2 i =M 
A2 i =M
A2 i =M 



c2 (  t10 )  c2 (  t)  (
A1i  B

A2 i =B

c2
)(  t)  (2c2 )(  t)+(c1  c2 )(  t).
2 A2 i =B 
A2 i =B 
A2 i =M  B

Similarly, the cost for the time-varying SMART in Figure 2 is

cos t  c1 (

 T )c ( 

A1i  M

1i

1

t)  (2c1 )(

A2 i =M

c2 (  T1i )  c2 (  t)  (2c2 )(
A1i  B

A2 i =B



t) 

A2 i =M 



A2 i =B 

t)+(c1  c2 )(
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A2 i =M  B

t),

and the cost for the corresponding standard SMART in Figure 4 is

cos t  c1 (

t

A1i  M

10

)  c1 (



t)  (2c1 )(

A2 i =M

c2 (  t10 )  c2 (  t)  (2c2 )(
A1i  B

A2 i =B



t)+

A2 i =M 



A2 i =B 

t)  (c1  c2 )(



t).

A2 i =M  B

Note that in the above equations, T1i =t10 for non-responders, and (c1  c2 )(



t)

A2 i =M  B

is the cost of the second stage for all the subjects assigned to the intervention M+B.
Figure 5 shows the cost as a function of c1 and c2 , where red represents the
cost of the time-varying SMART design and blue represents the cost of the standard
SMART design. We can see that the cost of the time-varying SMART is less than
the cost of the standard SMART in all scenarios. Table 13 shows the average costs
and standard deviations calculated at select values of c1 and c2 based on 1000
replicates. For example, when the unit costs are c1 =2 and c2 =1 for medication and
behavioral intervention, the average cost of the time-varying SMART in Figure 1 is
3446.5, with standard deviation 49.87, while the average cost of the corresponding
standard SMART is 3935.8, with standard deviation 41.47. Thus, the cost of the
standard SMART is about 12% higher than that of the time-varying SMART in this
scenario.
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Figure 5.The cost associated with implementing a standard SMART (blue) and
equivalent time-varying SMART (red)

Table 13. Examples of the average cost for time-varying SMART and the standard
SMART.
Average Cost(SD)

Design in Figures 1 and
3: All the subjects are
re-randomized

Design in Figures 2 and
4: Only non-responders
are re-randomized

2.7

c1

c2

2

Time-varying
SMART

Standard
SMART

1

3446.5(49.87)

3935.8(41.47)

1

1

2325.7(29.82)

2631.4(19.15)

1

2

3526.5(57.00)

3953.2(46.63)

2

1

3593.4(45.40)

4056.9(36.52)

1

1

2416.1(24.12)

2704.9(14.59)

1

2

3655.5(53.53)

4056.7(42.77)

Discussion
The proposed time-varying two-stage SMART design can take into account

the time associated with the first-stage interventions and thus could result in clinical
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trials with fewer side effects and lower expected cost. Additionally, the two modeling
approaches we proposed are able to provide good estimations of the means of the
final outcomes of all the embedded interventions. The joint modeling approach
resulted in more accurate estimates and higher estimated coverage probabilities;
therefore, we recommend using joint modeling to analyze data generated from the
time-varying designs proposed in this manuscript.
In the standard SMART design, the timing of the intervention is generally
ignored, which leads to a model of regression without the predictor of a time
variable. Therefore, in this article, we proposed a time-varying SMART design that
allows the re-randomization to the second-stage interventions to occur at different
times for different individuals. The two modeling approaches we proposed for
analyzing data using such time-varying designs provided good estimations of the
means of the final outcomes of all the embedded interventions. However, the joint
modeling approach provided more accurate parameter estimates and higher
estimated coverage probability than the TVMEM, and we recommend the joint
model for analyzing data generated from time-varying designs.
In the examples illustrated in Figures 1 and 2, a participant was defined as a
responder if there was a significant decrease in the number of cigarettes the
participant smoked per day. One may question the validity of re-randomizing
individuals who have a quick response to the first-stage intervention because such
a response indicates the effectiveness of the intervention. However, if significant
adverse effects are associated with the intervention (e.g., radiation therapy for many
types of cancer is commonly associated with skin damage(143), fatigue(144),
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diarrhea(145,146), and rectal bleeding(147)), it is reasonable to shorten the duration
of the intervention to avoid side effects. Therefore, the allocation strategy for the
responders in the examples of the time-varying SMART design makes it more
efficient than the standard SMART design.
We proposed two approaches for analyzing the longitudinal outcomes
obtained from the time-varying SMART design: the TVMEM and the joint model.
According to the simulation results, the joint modeling approach better estimated the
effects of the timing of the intervention (i.e., T2 ) and the first-stage interventions (i.e.,
A1 ) in model (4). More specifically, the joint modeling approach had more accurate

estimates, smaller MSEs, higher estimated coverage probabilities, and smaller 95%
confidence intervals (i.e., smaller estimated standard deviations) for the coefficients
of the effects of the first-stage intervention and the time of intervention. Because we
wanted to illustrate the cost efficiency of the proposed time-varying SMART design
and its ability to select the optimal embedded adaptive intervention, we
implemented a rather simplified linear mixed-effects submodels (2)-(4) of the more
general TVMEM in model (1). We showed that the joint model performs better than
the TVMEM in analyzing the data collected from such time-varying SMART designs.
The joint modeling approach extracts part of the information contained in the time of
the response, which is a function of the first-stage treatment assignment. Also, the
association between the longitudinal and event outcomes is accounted for by the
random effect that underlies both the longitudinal and survival processes for each
subject. Therefore, although complex, time-varying SMART designs may require
more complicated models for time and an extra layer of joint modeling, and as such
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one would expect a better performance from joint modeling in general. Nevertheless,
both modeling approaches performed well in estimating the other parameters and
the mean of the final outcomes for each adaptive intervention embedded in the
corresponding designs. Furthermore, equation (1) is a general form of TVMEM, and
in our study is equivalent to equations (2) ~ (4) at time points t  0, T1i , T2i for each
subject i . T1i is a subject-specific random variable, and coefficients in equation (3)
can also be subject-specific. However, in practice, modeling coefficients to be
subject-specific may lead to the estimation of too many parameters which, in some
scenarios, may not be identifiable, particularly with small sample sizes. Therefore,
as an initial attempt, we modeled T1i as a subject-specific random variable and the
coefficients as fixed parameters. For example, coefficients  0 (t ) , 1 (t ) ,  3 (t ) in
equation (1) are fixed coefficients  01 , 11 , 31 in equation (3), as model (1) is
equivalent to submodel (3) at time point T1i . More complicated models such as
subject-specific and time-varying coefficients in submodels (2)-(4) can be
considered, if the sample sizes are large.
We also illustrated the effectiveness of the joint modeling approach in
accurately estimating the parameters even when no specific model was assumed
for the duration of the first-stage intervention, T1i . The conclusions were qualitatively
similar as that in the simulation where Weibull model was assumed for the duration
of the first-stage intervention.
In the scenarios we considered here, the time at which individuals were rerandomized was assessed only for responders to the first-stage intervention.
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However, one may also consider varying times for the non-responders and for the
second-stage interventions. For example, a non-responder showing severe side
effects or no trend towards achieving intermediate goals may be re-randomized
sooner than t10 . The analytic approaches for such designs would be similar to the
joint or time-varying mixed effects models proposed in this manuscript, for example,
with an extra submodel for the duration of the second-stage interventions. Instead
of randomization with certain pre-defined probabilities (e.g., in the first two
simulation scenarios, randomization with probability 0.5 was used for both stages; in
the last two scenarios, unequal randomization with probabilities 0.4(0.6) and
0.55(0.45) was used for the two stages, respectively), information concerning
potential moderators could be used to tailor and assign the interventions. For
example, the choice of the first-stage intervention options could depend on the
severity of the subject’s smoking habit at the beginning of the study; whereas the
choice of the second-stage intervention option could depend on the subject’s
adherence to the first-stage intervention. The analysis of such a randomization
scheme would require assigning weights each subject(148).
We also compared the cost and power associated with selecting the optimal
embedded adaptive intervention for the proposed time-varying SMART design
versus that for the analogous standard SMART design. Our simulation results
showed similar power for the two designs. We used a linear cost function to assess
the cost efficiency of the proposed design and found that it can have substantially
lower expected cost than the standard design. Several other forms of cost functions
can be used to assess cost efficiency. However, as long as the cost is an increasing
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function of time, the proposed time-varying SMART design will have lower expected
cost than the standard SMART design. Therefore, the time-varying SMART design
can be used to study how the intensity and combination of two types of
interventions might be adapted to a subject’s progress in a cost- and time-efficient
manner.
In our study, we assume that there is no unmeasured confounder. As
suggested by Chakraborty and Murphy(63), the assumption of “no unmeasured
confounders” holds in a SMART design if the randomization probabilities of A1 at
most depend on the baseline covariates, and the randomization probabilities of A 2
at most depend on the baseline covariates, the intermediate outcome, and A 1. We
performed additional simulations to investigate the role of unmeasured confounders
on the parameter estimations. From these simulations, we see that when the
unmeasured confounders affect only T1 and Y1, the parameter estimation is still
accurate (see Appendix: Table S4). However, when these unmeasured confounders
affect Y2, there is bias in the estimation of T2 (see Appendix: Tables S5-S6).
In the ADHD SMART study discussed by Nahum-Shani et al.(76), a weighted
average was applied to the final outcomes when their primary goal of analysis was
to compare the imbedded adaptive intervention options in the design. In our TimeVarying SMART study, we used regression-based methods to identify more efficient
adaptive decision rules for each subject along with their longitudinal outcomes.
Similar to the analytic process of the standard SMART design by Q-learning5 in
which a regression model for the outcome is postulated at each decision as a
function of the patient’s information to that point, our TVMEM in equation (1) is
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equivalent to submodels (2)-(4) at three time points of longitudinal outcomes for
each individual. Therefore, we did not include weights in this study of the timevarying SMART design. However, for increased complexity of time-varying SMART
designs, weights may be incorporated into the analysis in a future study to develop
more robust estimations and results.
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A Bayesian response-adaptive, covariate-balanced and
optimal-decision-consistent randomization method for SMART
designs
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3.1 Materials and methods
3.1.1 Existing randomization strategies for SMART
In sequential multiple assignment randomized trial (i.e., SMART) designs(76),
various randomization strategies have been developed to allocate subjects into the
embedded interventions. Besides the standard total randomization in which subjects
are randomized into different interventions with equal probability, subjects can also
be assigned to the interventions according to their baseline characteristics,
intermediate covariates or intermediate outcomes, or historical information. The
goals of such allocation schemes are to assign subjects to the superior
interventions with higher probabilities. Different kinds of allocation methods can be
found in the clinical trial literature. Response-adaptive randomization, in which
allocation probabilities are adjusted based on the previous patients’ responses in
the study, allow more patients to be assigned to the superior treatment as the trial
progresses. For example, Efron(149) proposed a biased coin design to balance the
numbers of individuals in the experimental treatment and control arms while
avoiding various experimental biases; Berry and Eick(150) compared a balanced
randomization strategy to adaptive randomization in clinical research; Rosenberger
et al.(151) developed an optimal allocation between two treatments in a clinical trial;
Thall, Inoue and Martin(152) proposed an adaptive Bayesian design for patients
with hematologic malignancies; Zhang and Rosenberger(153) evaluated the
performance of different response-adaptive randomization procedures in clinical
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trials with continuous outcomes; and Sverdlov et al.(118) proposed a multipleobjective response-adaptive design.
However such response-adaptive designs lead to covariate imbalance, which
results in bias when comparing treatment efficacy. Several methods have been
proposed to balance covariate distributions across intervention arms during
randomization. For example, Signorini et.al.(120) proposed a randomization method
for balancing treatment allocations both within strata and across the trial. This
approach was further improved by Heritier, Gebski and Pillai(154) to maintain a
marginal balance over important strata. Thall and Wathen(86) proposed a Bayesian
design for a multi-center, randomized clinical trial using covariate-adjusted adaptive
randomization. Shao and Yu(155) established asymptotic results for covariateadaptive biased coin randomization under generalized linear models. Recent
research efforts have combined these two approaches. For example, Ning and
Huang(122) developed a patient allocation scheme for trials with binary outcomes to
adjust the covariate imbalance during response-adaptive randomization. In
particular, Yuan et al.(123) proposed a randomization procedure and incorporated
this method into a group sequential response-adaptive randomization design with a
goal of achieving the benefits of the response-adaptive design while balancing the
covariates. These methods have the advantage of assigning fewer patients to
inferior treatments or controlling the imbalance of covariates across treatments
when the sample size is moderate or small. Scott et al.(156) and Green(157)
provided comprehensive reviews on the allocation method of minimization for
balancing treatment groups.
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However, these randomization strategies are not straightforward to apply for
SMART designs because participants are re-randomized in multiple stages and
embedded interventions are involved in such a design. There are several
optimization strategies for choosing the interventions for subjects in the SMART
design. One of the most recently developed methods is Q-learning(103,131), which
selects the optimal intervention for each subject according to the Q-learning
regression model at each stage. The Q-learning algorithm estimates both the direct
and indirect effects of the first-stage intervention options while controlling for the
optimal second-stage intervention option when assessing the effect of the first-stage
intervention. It also reduces the potential bias resulting from unmeasured causes
associated with both the tailoring variables and primary outcomes.
In this article, we propose a randomization method that takes into account the
Q-learning optimization while also being response-adaptive and balancing
covariates between competing interventions at each stage of SMART. This
approach, instead of randomizing the subjects all at one time, uses a more practical
approach, assigning the subjects to treatments in sequential groups with a
response-adaptive, covariate-balanced and decision-consistent probability based on
the information obtained from previously enrolled groups. We performed simulation
studies to compare the proposed allocation strategy to other possible allocation
strategies.
3.1.2 Methods
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The proposed allocation procedure for SMART is response-adaptive and also
optimizes each individual’s intervention based on the Q-learning algorithm while
balancing the covariates(123,158) across all available interventions at each stage of
the SMART design. This strategy is applied to SMART in a group sequential
manner such that the resulting design skews the allocation probability to the better
interventions to optimize the final outcomes and lowers the covariate imbalance
based on the information from previous participants. Specifically, subjects enroll into
a SMART in sequential groups of sizes {Nk },k=1,. . . , K , where N k is the sample
size of the kth group. The subjects enter the trial sequentially and the allocation
probabilities are updated using the observed data from previous participants
enrolled in the study. If little information regarding the superiority of the interventions
is known before conducting the trial, subjects in the 1st (k=1) group are allocated
randomly to the interventions at both stages of SMART, i.e., the allocation
probability is 0.5. Other randomization probabilities can be applied to the first group
if historical information regarding the embedded interventions is known before the
trial, or based on the baseline characteristics, intermediate covariates or
intermediate outcomes of the subjects. For subsequent groups (k=2,…,K),
calculations of the allocation probability are described below. We motivate our
methodology with a standard two-stage SMART design (depicted in Figure 7) in
which subjects in the first stage are randomized into one of two interventions:
medication (A1=+1) or behavioral intervention (A1=-1). At the second stage, only
non-responders from the first stage are re-randomized to either increase the dose of
the initial intervention (A2=+1) or add the alternative intervention (A2=-1).
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Figure 6. SMARTs in which re-randomization to different second-stage
intervention options depends on an intermediate outcome (only nonresponders are re-randomized in the second stage)

Let O1 be the baseline covariates assessed before the first-stage intervention
(e.g., level of depression, sex, age, etc.) and O2 be the intermediate covariates
assessed prior to the second-stage intervention (e.g., adherence to the first-stage
intervention). Let Y be the final outcome value at the end of the trial.
3.1.2.1

Decision-consistent randomization probability by Q-learning
optimization

First, we briefly introduce the Q-learning approach, which can be used to
develop adaptive interventions from the data(103,131). In Q-learning, optimal
decisions are derived by maximizing the Q-functions if a higher value of outcome is
desired (minimizing the Q-functions if a lower value of the final outcome is desired).
The Q-function of the second stage is
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Q2 (O1 , A1 , O2 , A2 ,  2 ,  2 )   20   21O1   22O2   23 A1   24 A1  O1  ( 20   21 A1   22O2 )  A2
where O1  (O11 , O12 ,...) and O2  (O21 , O22 ,...) are the respective vectors of the
baseline and intermediate covariates. The parameters  2  ( 20 ,  21 ,  22 ) reflect how
the second-stage intervention (A2) varies as a function of the candidate tailoring
variables (here, A1 and O2). Based on this equation, the second-stage intervention
option (A2) that maximizes Q2 is the one that maximizes the term
(α20 + α21A1 + α22O2)A2. If (α20 + α21A1i + α22O2i) >0, the term
(α20 + α21A1i + α22O2i)A2i attains its maximal value for A2i = 1; and if
(α20 + α21A1i + α22O2i) < 0, the term (α20 + α21A1i + α22O2i)A2i attains its maximal
value for A2i = −1. Therefore, the optimal second-stage decision for subject i is
d 2*i  sign(20  21 A1i  22O2i ) .

In our proposed approach, the allocation probability utilizes the optimal
decisions derived from the Q-learning algorithm(103,131) for SMART designs. We
estimated the parameters in the model

Yi ~  20   21O1i   22O2i   23 A1i   24 A1i  O1i  ( 20   21 A1i   22O2i )  A2i using a Bayesian
linear regression model with the data from the previous k-1 groups, i.e., Dk . In this
Bayesian approach, we assume a vague normally distributed prior N (0,106 ) for all
model parameters, which is a commonly used type of priors when little information
is known about the parameters.
The estimated posterior means of the parameters are denoted by
( 20 ,  21 ,  22 ,  23 ,  24 ,  20 ,  21 ,  22 ) . Therefore, the decision-consistent probability
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according to Q-learning optimization for assigning subject i to the second-stage
intervention A2=1 is
pkiD (2)  Pr( 20   21 A1i   22O2i  0 | Dk )

(1) . Then, we move backwards in time to

construct the first-stage decision-consistent probability by maximizing the first stage
Q-function: Q1 (O1 , A1;  1 , 1 )   10   11O1  (10  11O1 )  A1 , which leads to the optimal
first-stage decision d1*i  sign(10  11O1i ) (103,131) . We then estimate  1 , 1 in
model Y i ~  10   11O1i  (10  11O1i )  A1i using a Bayesian linear regression. Here Y i
is the maximal value of the Q2 –function calculated with
( 20 ,  21 ,  22 ,  23 ,  24 ,  20 ,  21,  22 ) if subject i is a non-responder to the first-stage

intervention; it is equal to Yi if subject i is a responder to the first-stage intervention.
In this regression, we also assume that the coefficients in the above model have a
prior distribution N (0,106 ) . Finally, the first-stage decision-consistent probability for
subject i to A1=+1 is
pkiD (1)  Pr(10  11O1i  0 | Dk )

3.1.2.2

(2) .

Covariate-balanced randomization probability according to the
prognostic score

The part of covariate-balanced probability pkiC (2) for each subject i

(i  N  (k  1)  1,..., N  k ) in the k th (k  1,..., K ) group is derived from the Bayesian
marginal model of the second stage Y ~ 20  21O1   22O2   23 A1   24 A2   25 A1  A2 ,
1
,  222 ,...) reflect the importance
where the coefficients 21  ( 211 ,  212 ,...) and  22  (  22
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of the baseline covariates O1  (O11 , O12 ,...) and intermediate covariates

O2  (O21 , O22 ,...) in predicting the final outcomes. All the coefficients in this model are
assumed to have normal distributions with vague prior N (0,106 ) , and their posterior
means are estimated as  2  ( 20 ,  21 ,  22 ,  23 ,  24 ,  25 ) by MCMC regression with

datak . The prognostic score for subject i in group k is defined as

w2i  21O1i  22O2i , i  N  (k  1)  1,..., N  k (100,123). This definition allows us to
balance the covariates through the single variable w1i while accommodating both
categorical and continuous covariates in O1i and O2i . Let w A1 , A2 be the vector of the
current prognostic score for the non-responders who received interventions (A1, A2),
which is calculated with the estimated posterior means  2 . Then KS A1i , A2 ,i , A1  1 or -1
are the two Kolmogorov-Smirnov (KS) statistics(159,160) for subject i who received
intervention A1i at the first stage and was then assigned to the second-stage
intervention A2 ( A2  1 or -1) based on w A1i , A2 1 and w A1i , A2 1 . Because higher values
of the KS statistics indicate more severe imbalance, the covariate–balanced
probability of assigning subject i to intervention A2=1 at the second stage is defined
as
pkiC (2) 

KS A1i , A2 1,i
KS A1i , A2 1,i  KS A1i , A2 1,i

(3) .

To avoid extreme values (i.e., values close to 1 or 0) in certain circumstances,
a root transformation such as that suggested by Yuan et al. (123,158) can be
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(2)
applied to stabilize the probability in (8) as pkiC,stablized
=

pkiC (2)
pkiC (2) + 1-pkiC (2)

. We still use

(2)
for simplicity.
pkiC (2) to denote pkiC,stablized

At the first stage, the probability of randomizing subject i to the intervention
A1=1 is pkiC (1) 

KS A1 1,i
KS A1 1,i  KS A1 1,i

(4)

where KS A1 1,i and KS A1 1,i are the two KS statistics calculated for subject i when
assigned to the first-stage intervention A1=1 and A1=-1, respectively. The probability
in (4) may also be stabilized by the aforementioned root transformation.
3.1.2.3

Response-adaptive randomization probability based on outcomes of
previous groups

The final outcomes (Y) of the intervention ( A1 , A2 ) at the second stage are
assumed to follow a normal distribution with mean  A1 , A2 which are further assumed
to be normally distributed with vague priors N (0,106 ) . The posterior distribution of
(k )

(k )

 A , A follows a normal distribution, N ( A1 , A2 , A1 , A2 ) . Therefore, the posterior
1

2

(k )

(k )

distribution of the difference  a1 , A2 1  a1 , A2 1 is normal with mean  a1 , A2 1   a1 , A2 1
(k )

(k )

and variance ( a , A 1 )2  ( a , A 1 )2 . If higher values of the final outcomes are desired,
1

2

1

2

the response-adaptive randomization probability for intervention A2=1 at the second
stage is calculated as: pkR (2)  Pr( a1 , A2 1 a1 , A2 1  0 | Dk )
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(5)

for a subject who received A1=a1 as the first-stage intervention. This probability is
common for all the subjects in the kth group and may also be stabilized with a root
(2)
transformation: pkR,stablized
=

pkR (2)
pkR (2) + 1-pkR (2)

.

Similarly, the probability of randomizing subjects to interventions A 1=1 at the
first stage is calculated by MCMC regression as
pkR(1)  Pr( A1 1  A1 1  0 | Dk ), k  2,..., K

(6) ,

where  A1 1 and  A1 1 are the means of the final outcomes for subjects who
received first-stage interventions A1=1 and A1=-1, respectively.
With different combinations of the three types of allocation probabilities above,
we developed different randomization methods, which we describe in the next
section.
3.1.2.4

Response-adaptive, covariate-balanced and decision-consistent
(RCD) randomization method

The response- adaptive, covariate-balanced and decision-consistent allocation
probability of assigning each individual i in the k th group to intervention As =1 at the

s ( s  1, 2) stage is pki( s )  pkR ( s )  pkiC ( s )  pkiD ( s ) , s  1, 2; k  1,..., K ; i  1,..., n

(7) ,

where pkR ( s ) , pkiC ( s ) and pkiD ( s ) are the response-adaptive, covariate-balanced and
decision-consistent probabilities, respectively. Data from the first k groups, i.e.,

datak , are used for calculating the allocation probability for the subjects in the
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(k+1)th group. Therefore, the allocation probabilities are updated with data from the
ongoing trial.
3.1.2.5

Response-adaptive and decision-consistent (RD) randomization
method

Because the SMART design is adaptive to each individual’s characteristics, in
cases in which balancing the covariates between two competing interventions is not
as important as optimizing the final outcomes and decisions during randomization,
the allocation probability can be further simplified to be only response-adaptive and
decision-consistent. This is the RD randomization method in which the allocation
probability to As =1，s  1, 2 for each subject i in the k th group is defined as
pki( s )  pkR ( s )  pkiD( s ) , s  1, 2; k  1,..., K ; i  1,..., n

(8) ,

where pkR ( s ) and pkiD ( s ) are the respective response-adaptive and decision-consistent
probabilities.
3.1.2.6

Other randomization methods

There are other existing randomization strategies or straightforward
extensions of randomization strategies based on the allocation probabilities defined
above that can be applied to SMART designs. Using the definitions in equations (1)
~ (6) above, we define the following randomization strategies. The response
adaptive randomization (R) is similar to the Bayesian response-adaptive
randomization design(153,161) for which the randomization probability is
pk(is )  pkR( s )

(9) ;
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the covariate-balanced randomization (C) is similar to the Pocock and Simon
strategy(162) for which the randomization probability is pi( s )  pkC ( s )

(10) ;

the combination of the response-adaptive and covariate-balanced randomization
(RC) is similar to that proposed by Yuan et al.(123) for which the randomization
probability is pk(is )  pkR( s )  pkiC ( s )

(11) ;

the decision-consistent randomization (D) according to the Q-learning optimization
for which the randomization probability is pki( s )  pkD( s )

(12) ;

the covariate-balanced and decision-consistent randomization (CD) for which the
randomization probability is pk(is )  pkC ( s )  pkiD( s )

(13) ;

and the total randomization at both stages (T), the probability for which is
pki( s )  0.5

(14) .

3.2 Simulation models and assessment methods
We applied the proposed and existing randomization methods to the SMART
design (see Figure 6). We used simulation studies to evaluate the proposed
response-adaptive, covariate-balanced and decision-consistent randomization
(RCD) method and the response-adaptive and decision-consistent randomization
(RD) method, and compared them with covariate-balanced and decision-consistent
randomization (CD), decision-consistent randomization (D) and other existing
randomization methods used in standard clinical trials such as response-adaptive
and covariate-balanced randomization (RC), total randomization (Total), response-
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adaptive randomization (R), and covariate-balanced randomization (C), for which
the corresponding probabilities are defined in (8)~(14).
We generated data for subject i using the following model

Yi   20   21O1i   22O2i   23 A1i   20  A2i   21 A1i  A2i   24 A1i  O1i   22 A2i  O1i + i ,  i ~N (0,1)

where A1 and A2 are intervention indicators of the two stages of SMART; O1 is the
baseline covariate vector and O2 is the intermediate covariate vector. The results
reported in tables are based on 1000 replicates. For each comparison, we carried
out simulations with complete (probability equal to 0.5) and unequal randomization
(i.e., the probability of randomizing a non-responder in the first group depends on
the value of his/her intermediate covariates, O2 ). The model parameters were
estimated using the “MCMCpack”(163,164) package in R.
We considered three summary measures to compare the proposed and
existing randomization strategies. We used the percentage of the inferior treatment
number (ITN%), which is the percentage of subjects who were assigned to the
inferior intervention arms (i.e., interventions for which the expected final outcomes
are lower than those expected for the competing interventions). We also calculated
the KS statistic for the prognostic score. We report the percentage of the
occurrence of significant covariate imbalance, i.e., for each of the two first-stage
interventions: A1=1 and A1=-1, we report the percentage of the p-values of the KS
statistic that is less than 0.05. In addition, we report the percentage of subjects
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(15)

assigned to their optimal adaptive strategies according to the Q-learning algorithm
(ODQ%).

3.3 Simulation results
Tables 14–17 show the simulation results based on the SMART in Figure 6.
Data for the simulations were generated using model (15) with the following
parameter choices:  20 =1 ,  21 =1， 22 =-1， 23 =-0.3 ,  24 =0.1， 20 =0.1， 21 =-0.2 and

 22 =-0.2 . The values of O1 and O2 , which are univariate covariates, were generated
from the normal distributions N (3,12 ) and N (0.1, 0.32 ) , respectively.
In Table 14, the total study sample size is 200 individuals and the group size is 40,
i.e., the allocation probability is updated for each sequential group of 40 subjects.
The non-responders in the first group were assigned to the second stage
intervention based on their intermediate covariate O2 (i.e., unequal randomization).
Specifically, a non-responder was assigned to the intervention A2 =1 with probability
equal to the cumulative normal distribution at his/her observed O2 value. As shown
in the table, the percentages of the subjects who were assigned to the inferior
intervention arms were 22.73% and 21.96% for the RCD and RD methods,
respectively, which were lower than those for the other methods. These two
methods also had the highest percentage of subjects assigned to the most optimal
adaptive strategy: 67.21% and 67.99% compared to RC (59.91%), CD (62.09%), D
(62.60%) and R (60.51%). As expected, the ODQ% was 50.13% and 50.24% for
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the TR and C methods, respectively. Importantly, the proposed RCD method had an
acceptable percentage of significant covariate imbalance (2%, 2%) compared with
that of the RD (8.5%, 7%), D (7.5%, 6%), and R (8.5%, 9%) methods for each of the
two first-stage interventions: A1=1 and A1=-1. The level of imbalance for the RC, CD,
TR and C methods was also acceptable.

Table 14. Simulation results based on 1000 replicates for SMART in Figure 6 with
parameter values  20 =1 ,  21 =1,  22 =-1,  23 =-0.3 ,  24 =0.1， 20 =0.1， 21 =-0.2 and

 22 =-0.2 ; the sample size was 200 with group sizes of 40 and the non-responders in
the first group were assigned to the second-stage intervention based on their
intermediate outcome O2 (i.e., unequal randomization).
Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

22.73%

2.0%

2.0%

67.21%

RD

21.96%

8.5%

7.0%

67.99%

RC

27.91%

3.5%

2.5%

59.91%

CD

26.39%

1.0%

1.0%

62.09%

Total

34.94%

5.0%

6.5%

50.13%

D

26.12%

7.5%

6.0%

62.60%

R

27.46%

8.5%

9.0%

60.51%

C

35.20%

1.5%

1.5%

50.24%

In Table 15, we present results for the same sample sizes and the same
parameter configurations as in Table 1 except instead of unequal randomization, we
applied complete randomization to the first group in the trial (i.e., subjects were
randomized into the two interventions with probability 0.5). Overall, the results are
similar to those shown in Table 1. The RCD method had the lowest ITN% (21.97%)
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and the highest ODQ% (68.35%), which is similar to those respective values for the
RD method: 22.86% and 67.30%. The TR and C methods showed the highest ITN%
(34.64% and 34.66%, respectively) and lowest ODQ% (50.60% and 50.49%)
among all the methods. The RCD method had an acceptable level (2.5%) of
significant covariate imbalance for each of the two first-stage interventions: A1=1
and A1=-1. The percentage of significant covariate imbalance for the various
methods was RC (3% and 1%), CD (3.5% and 2.5%), C (2.5% and 1%), RD (6.5%
and 4%), D (6.5% and 5%), TR (6% and 4.5%) and R (8% and 5.5%).
Table 15. Simulation results based on 1000 replicates for SMART in Figure 6 with
parameter values  20 =1 ,  21 =1， 22 =-1， 23 =-0.3 ,  24 =0.1， 20 =0.1， 21 =-0.2 and

 22 =-0.2 ; the sample size was 200 with group sizes of 40 and the non-responders in
the first group were assigned to the second-stage intervention completely at random
(i.e., equal randomization)
Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

21.97%

2.5%

2.5%

68.35%

RD

22.86%

6.5%

4.0%

67.30%

RC

27.16%

3.0%

1.0%

61.05%

CD

25.70%

3.5%

2.5%

63.36%

Total

34.64%

6.0%

4.5%

50.60%

D

25.87%

6.5%

5.0%

63.02%

R

27.87%

8.0%

5.5%

60.04%

C

34.66%

2.5%

1.0%

50.49%

Table 16 shows the results for the same simulation parameters as shown in
Table 1, except that the group size is 100, with a total sample size of 500. Similar to
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the results in Table 1, the RCD and RD methods had lower ITN% (17.49% and
17.15%, respectively) and higher ODQ% (74.41% and 74.80%, respectively) than
the other methods. The percentage of significant covariate imbalance for the RCD
method was (7.5%, 9%); whereas that for the RD method was (11.5%, 13%).
Although the percentage of significant covariate imbalance was acceptable for the
TR and C methods, 4%, 7% and 3.5%, 3% respectively, these methods had higher
ITN% (35.03% and 34.84%, respectively) and lower ODQ% (49.74% and 49.96%,
respectively) when compared to the other methods.
Table 16. Simulation results based on 1000 replicates for SMART in Figure 6 with
parameter values  20 =1 ,  21 =1,  22 =-1,  23 =-0.3,  24 =0.1， 20 =0.1， 21 =-0.2 and

 22 =-0.2 ; the sample size was 500 with group sizes of 100; and the non-responders
in the first group were assigned to the second-stage intervention based on their
intermediate outcome O2 (i.e., unequal randomization).
Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

17.49%

7.5%

9.0%

74.41%

RD

17.15%

11.5%

13.0%

74.80%

RC

22.66%

3.0%

2.5%

66.98%

CD

21.93%

7.0%

6.5%

69.05%

Total

35.03%

4.0%

7.0%

49.74%

D

21.79%

10.5%

11.0%

68.95%

R

22.38%

4.5%

5.5%

67.32%

C

34.84%

3.5%

3.0%

49.96%

Table 17 shows the results of the same simulation parameters as shown in
Table 2, except that the group size is 100 and the total sample size is 500. The
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RCD method again showed the best performance with respect to all three statistics,
i.e., lowest ITN% (18.44%) and highest ODQ% (73.39%) among all the methods
with acceptable percentages of significant covariate imbalance (4%, for both first
stages). Meanwhile, the RD method had ITN% (19.85%) and ODQ% (71.52%)
close to those from the RCD method, but had higher covariate imbalance (11%,
9%). Both the CD and D methods had higher ITN% (21.25% and 21.47%,
respectively) and lower ODQ% (69.63% and 69.3%, respectively) than the RCD and
RD methods.

Table 17. Simulation results based on 1000 replicates for SMART in Figure 6 with
parameter values  20 =1 ,  21 =1， 22 =-1， 23 =-0.3 ,  24 =0.1， 20 =0.1， 21 =-0.2 and

 22 =-0.2 ; the sample size was 500 with group sizes of 100; and the non-responders
in the first group were assigned to the second-stage intervention completely at
random (i.e., equal randomization).
Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

18.44%

4.0%

4.0%

73.39%

RD

19.85%

11.0%

9.0%

71.52%

RC

23.07%

2.0%

1.5%

66.47%

CD

21.25%

5.5%

4.5%

69.63%

Total

35.02%

3.0%

5.0%

49.97%

D

21.47%

9.5%

6.0%

69.30%

R

23.85%

4.5%

5.5%

65.75%

C

35.17%

2.5%

2.5%

49.75%

3.4 Discussion
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We have proposed a Bayesian response-adaptive, covariate-balanced and
optimal Q-learning decision-consistent randomization strategy (RCD) for SMART
that successfully combines the advantages of the response-adaptive randomization
strategy and the covariate-balanced randomization strategy while having the
highest consistency for the optimal interventions derived by the Q-learning algorithm.
In this approach, the assignment probability for a new subject who enters the
SMART depends on his/her covariates and the previous subjects’ treatment
assignments and responses. In this method, more subjects are assigned to the
better interventions because the randomization probability uses the individual’s
optimal decisions under the Q-learning algorithm, which leads to higher ODQ%.
The second approach (RD) that we suggested combines the decisionconsistent probability (i.e., randomization according to the individuals’ optimal
decisions derived by Q-learning) with the response-adaptive probability (i.e.,
randomization according to the final outcomes). This method has the advantages of
the two strategies: response-adaptive and decision-consistent randomization, i.e.,
low ITN% and high ODQ%, however, the method leads to higher imbalance than
the RCD method, especially when the first group in the trial was randomized
according to the intermediate covariates, as demonstrated in the simulation studies.
Both the CD and D methods showed higher ITN% and lower ODQ%, while the D
method also had less controlled covariate balance than the RCD and RD methods.
For all the methods, when the group sizes were larger, the observed
imbalance was higher, as seen by comparing Tables 16 and 17 to Tables 13 and 14.
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The parameters can be better estimated using the larger group sizes, however,
because each subject was allocated based on only the covariate imbalance of the
previous groups, the assignment of the current group of subjects was “over-skewed,”
which resulted in higher covariate imbalance.
This trade-off needs to be taken into account when randomizing subjects into
a SMART. We can use simulations to determine the appropriate group size. In
many behavioral interventions, relatively smaller group sizes (e.g., 10 or 20) are
used, therefore, the proposed methods are appropriate in such scenarios.
We illustrated the proposed methods and compared them to other
randomization strategies by applying them to the two-stage SMART in Figure 6.
They can also be applied to multi-stage SMART (i.e., SMART with more than two
stages) and the allocation probabilities of the sth stage are defined similarly to those
in equation (7) for the RCD method and equation (8) for the RD method.
The proposed RCD method combines the three parts of adaptive probabilities
in a multiplicative manner; however other combinations can also be used. For
example, one may define the allocation probability for subject i as

 2 and  3 can be any monotonic
pi( s )  1 ( pkR ( s ) )  2 ( pkiC ( s ) )  3 ( pkiD ( s ) ) where 1，
increasing function. In addition, one can also weight the three probabilities
unequally in order of their importance in the treatment assignment strategy.
Furthermore, the randomization probabilities can be updated as frequently as one
wishes and the group size can be adjusted to serve this purpose.
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In our simulations, we updated the randomization probabilities after each
group using vague priors for the model parameters in MCMC regression, which
allows for independent estimation of the parameters. One can also estimate the
model parameters using other priors such as distributions of historical data from
similar trials or the posteriors obtained based on previous groups. However, such
an approach may lead to an exclusive assignment to one of the interventions (i.e.,
subjects may all be assigned to one intervention) after several sequential updates,
which may lead to difficulty in parameter estimation and comparison of embedded
interventions in SMART. As a remedy, a mixture of this strategy and a
randomization strategy that has higher uncertainty can be applied.
Similar results were obtained for another type of SMART design (Figure S1),
where individuals were re-randomized irrespective of the intermediate covariates
(i.e., all the subjects were re-randomized at the second stage). See Supplementary
Information 4 and the results in Tables S7 and S8 in the Appendix.
In conclusion, among all the randomization methods we compared, the
proposed RCD randomization method showed the best performance in assigning
fewer subjects to the inferior interventions and more subjects to the optimal Qlearning interventions than the other methods while controlling the covariate
balance at an acceptable level when an appropriate group size was used.
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Conclusions and future directions
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4.1

Conclusions
In this dissertation study, I focused on investigating and utilizing the ability of

SMART to develop adaptive interventions for subjects involved in a multiple-stage
trial. To achieve this essential goal, we performed the study using the following twopart process. 1) We proposed a novel SMART design to reduce the side-effects
and cost associated with treatments, and the corresponding data analysis
approaches for such a design to estimate the effect of the treatment and the
treatment time. 2) We proposed a new randomization strategy for SMART to assign
more subjects to the optimal treatment while taking into account the overall
performance of each embedded intervention and the covariate balance among
subjects.
We first proposed the time-varying SMART, which is a novel design that takes
into account the treatment time as an endogenous variable. Rather than a fixed
period of treatment as that in the standard SMART design, each subject involved in
the proposed design moves to the next stage of treatment as soon as he/she
achieves certain pre-defined criteria (e.g., a pre-fixed threshold for the outcome of
interest), which potentially shortens the treatment time for the current stage. With
the simulation study, we show that such SMART designs can reduce the cost
and/or side effects associated with treatments while maintaining the same power as
the standard SMART design for selecting the optimal embedded intervention(s). We
also proposed the corresponding two modeling approaches, TVMEM and the joint
model for such a SMART design. We recommended joint modeling for data analysis
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after comparing the two modeling approaches with simulations. Joint modeling
provides better parameter estimation, while both methods show a good estimation
of the means of the final outcomes for all the embedded interventions.
Compared to the standard SMART design, the proposed time-varying SMART
design can accommodate more realistic situations and is more easily applied in a
clinical trial as it allows the treatment time to adapt to the subject’s response with
monitoring. The information regarding the treatment effects embedded in the
treatment time is utilized by the survival submodel in the joint modelling approach.
Therefore, the time-varying SMART design enables a more efficient study of
adaptive interventions and optimal intervention strategies with the ability to reduce
the associated cost and side effects.
In addition, we proposed a Bayesian response-adaptive, covariate-balanced
and optimal decision-consistent randomization method for SMART designs with the
goal to assign subjects in a way that is consistent with the scientific aims of SMART.
Based on existing randomization strategies developed for clinical trials, this new
method we proposed also takes into account the consistency of the optimal
intervention for each subject involved in a SMART with the use of the Q-learning
optimization algorithm. It balances the randomization considerations among the
three following parts: the average performance of each embedded intervention, the
covariate balance among all the subjects, and the optimal intervention for each
individual. The Bayesian framework is adopted into the proposed method and the
randomization probability is updated sequentially with divided groups. Based on our
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simulation study, we concluded that our proposed allocation strategy is more
appropriate for SMART than the existing methods for clinical trials because it takes
into account the individual optimization of the adaptive interventions while allowing
for ongoing updating based on the information accumulating during the trial.

4.2

Future directions
The time-varying SMART design we proposed can be extended to frameworks

with more flexibility. 1) We can vary the treatment time for both non-responders and
responders, which can be accommodated by defining another criterion for nonresponders and applying a strategy similar to that for responders and assigning the
subjects to the next stage of treatment. The treatment times for the two types of
treatment may need to be treated differently in the analysis. 2) We can vary the
treatment time of the second stage, which will introduce the variable of time for the
second-stage treatment and increase the complexity of the joint modeling if another
survival model is posted as well as the analysis of the combined effects of the firststage and second-stage treatments. 3) We can apply a multi-stage SMART design
with a varying treatment time for some or all of the stages, which may not be a
straightforward extension of the two-stage SMART design and will require advanced
modeling and computing strategies. (4) Similarly to the study of standard SMART,
we can also conduct sample size calculations or apply Bayesian framework on
TVSMART, Future studies can be conducted to assess these research topics.
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The optimization of the treatment time can be included in the study of timevarying SMART designs and the treatment time can be adapted to the individual’s
characteristics, needs and responses. This may also be done conditionally, i.e.,
finding the treatment time for the current stage based on the optimal treatment time
that has been used for the other stage for each individual. Therefore, the treatment
can be optimized regarding the type as well as its time of allocation. Furthermore,
the commonly used “early stopping rule” in clinical trials can be applied to SMART
designs.
In addition to the treatment time, other types of endogenous variables or
intermediate measurements on the causal pathway to the outcome of interest can
be embedded into SMART designs, with the corresponding analytic methods
properly accounting for them. Instead of approaches similar to joint modeling, we
may also consider strategies like principal stratification(165,166).
Because SMART designs have similarities to standard trial designs while
featuring unique characteristics, existing randomization methods can be applied
with some modifications such as forward or backward conditional computation for
multi-stage designs and cross-comparison among embedded interventions or
interventions at the same stage. Moreover, randomization methods for SMART
designs can be developed with respect to the goal of the study. For example,
different weights can be assigned to each part of the randomization probabilities
proposed in Chapter 3 to construct the overall allocation strategy based on different
priorities in the trial design and different research aims. In addition, choosing
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adaptive interventions for each individual can make use of optimization algorithms
other than Q-learning.
According to the simulation study in Chapter 3, an optimal group size for each
sequential update can be further investigated by taking into account the trade-off
between parameter estimation and covariate balance, as well as the power of
choosing the optimal intervention for each subject.
Although the new randomization method in Chapter 3 is developed for
standard SMART designs, it can be modified to accommodate the time-varying
SMART, for which the time of treatment is also taken into account duing
randomization and a more adaptive SMART is constructed. Following this line of
thinking, each design part of SMART can be potentially more adaptive to the
subjects while targeting the scientific aims of the SMART design.
The application of SMART designs can also be combined with traditional
methods and clinical trial designs, for which the SMART can be embedded into
certain parts of the trial and used to indicate intervention options. Strategies
developed for other types of clinical trial designs can also be used in certain stages
or parts of a SMART to achieve multiple analytic goals within one SMART.
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APPENDIX

Supplemental information:
1. Conditional expectation of TVMEM:
1.1 Models (1) - (4) can also be written in the form of conditional expectation
as
E[Yi | A1i (t ), A2i (t ), t ]  Z i  (t )   0 (t )  1 (t ) A1i (t )   2 (t ) A2i (t )  3 (t )t   4 (t ) A1i (t )  A2i (t )

E[Yi | t  0]  Z i 0   00

(2) ,

E[Yi | A1i , t  T1i ]  Z i 1   01  11 A1i  31T1i ( A1i )

(3) ,

and
E[Yi | A1i , A2 Ri , A2 NRi , t  T2i ]  Zi 2  02  12 A1i  22 A2 Ri  23 A2 NRi 

32T2i ( A1i , A2 Ri , A2 NRi )  41 A1i  A2 Ri  42 A1i  A2 NRi

(4).

1.2 Accordingly, the conditional expectation of the final outcomes for each of
the 8 embedded adaptive interventions in the SMART design of Figure 1 is
E[Yi |1,1,1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1,1,1)   41   42 for subjects

following adaptive intervention (A1=1,A2R= 1,A2NR=1);
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(1) ,

E[Yi |1,1, 1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1,1, 1)   41   42 for subjects

following adaptive intervention (A1=1,A2R= 1,A2NR=-1);
E[Yi |1, 1,1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1, 1,1)   41   42 for subjects

following adaptive intervention (A1=1,A2R= -1,A2NR=1);
E[Yi |1, 1, 1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1, 1, 1)   41   42 for subjects

following adaptive intervention (A1=1,A2R=- 1,A2NR=-1);
E[Yi | 1,1,1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1,1,1)   41   42 for subjects

following adaptive intervention (A1=-1,A2R= 1,A2NR=1);
E[Yi | 1,1, 1, t  T2i ]  Z i 2   02  12   22   23   32T2i (1,1, 1)   41   42 for subjects

following adaptive intervention (A1=-1,A2R= 1,A2NR=-1);
E[Yi | 1, 1,1, t  T2i ]  Z i 2   02  12   22   23  32T2i (1, 1,1)   41   42 for subjects

following adaptive intervention (A1=-1,A2R= -1,A2NR=1);
E[Yi | 1, 1, 1, t  T2i ]  Z i 2   02  12   22   23   32T2i (1, 1, 1)   41   42 for

subjects following adaptive intervention (A1=-1,A2R= -1,A2NR=-1).

1.3 The conditional expectation of the final outcomes for each of the 4
embedded adaptive interventions in the SMART design of Figure 2 is
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E[Yi |1,1, t  T2i ]  Z i 2   02  12   23   32T2i (1,1)   42 for subjects following adaptive

intervention (A1=1 ,A2NR=1);
E[Yi |1, 1, t  T2i ]  Z i 2   02  12   23  32T2i (1, 1)   42 for subjects following

adaptive intervention (A1=1, A2NR=-1);
E[Yi | 1,1, t  T2i ]  Z i 2   02  12   23  32T2i (1,1)   42 for subjects following

adaptive intervention (A1=-1,A2NR=1);
E[Yi | 1, 1, t  T2i ]  Z i 2   02  12   23  32T2i (1, 1)   42 for subjects following

adaptive intervention (A1=-1,A2NR=-1).

2

Data organization for Chapter 2
As discussed in the Methods, both analytic approaches required a linear

mixed model fitted in R by function “lme( )” in package “nlme”(167). Data obtained
from the design had to be organized longitudinally to apply this function. Therefore,
we stacked the observed data at three time points { 0, T1 , T2 } and formed a new data
set, as shown in Table A1. For each variable, the three parts of data in that column
represent the corresponding measurements for all the subjects at time points
{ 0, T1 , T2 }, respectively. The first column is the subject’s “id”, which is numbered from
1 to n (number of subjects), and thus the vector (1,2,…,n) is repeated for the three
parts in that column. The variable “Y” in the second column is the longitudinal
outcome of interest. Columns 3 to 14 represent the design matrix in models (2)–(4),
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and the corresponding coefficients are (  0Y0 ,  0Y1 ,  0Y2 , , 1 ,  21 ,  22 ,  23 ,  31 ,  32 , . 41 ,  42 ) .
Data analyses were conducted with the data organized in Table S3 using the two
proposed modeling approaches.

3

Implementation for Chapter 2
Data analysis using the joint model was implemented in R with package

“JM”(141). A linear mixed model was fitted for the longitudinal outcomes
Y  (0, Y1 , Y2 ) using function “lme( )” , and a Cox model was fitted for the time to the

event of interest, T1 . Then the outputs from these two models were supplied as the
main arguments in function “jointModel()” for fitting the joint model, using the data in
Table A1. (More specifically, the joint model fitted using “jointModel()” had exactly
the same structure for the linear mixed effects and survival submodels as these two
separately fitted models, with the addition that in the survival model the effect of the
estimated “true” baseline longitudinal outcome mi (0) was included in the linear
predictor.) This function approximates the integral

 p(T1 , 
i

i

| bi ;  ,  ,  , )[ p{Yi (t ij ) | bi ;  ,}]p(bi ;  b ) db using either the Gaussj

Hermite rule or the fully exponential Laplace approximation and the integral



T 1i

0

hi (s | mi (0);  ,  ,  , ) ds in the likelihood model of T 1i using the Gauss-Kronrod

rule. The maximization of the log-likelihood is based on a hybrid optimization
procedure, which starts with the expectation-maximization algorithm for a fixed
number of iterations, and if convergence is not achieved, switches to a quasi103

Newton algorithm(168) (method “BFGS” in R function “optim()”(169-171)) until
convergence is attained.
For all these options, the linear predictors in model (5) were written as

i   0   1 A1i   2Wi   mi {max(t  k,0)} where we let “parameterization = "value"” in
the function of “jointModel()”. Because in our example only the underlying baseline
measurement mi (0) was included in model (5), the linear predictor above should
satisfy mi {max(t  k, 0)}  mi (0) , which indicates that max(t  k, 0)  0 and (t  k)  0 . In
this expression, “t” is specified by the “timeVar” argument, which refers to the time
variable and “k” is specified by the “lag” argument, denoting a lag effect in the timedependent covariate represented by the TVMEM in the function “jointmodel()”.
Therefore, we set “timeVar” equal to “ T1 ” and “lag” equal to any value larger than

t10 (e.g., in the simulations, we set “lag=2” as t10 =1). In this way, we had max(tk,0)=0 for all the subjects and thus only the baseline longitudinal measurement was
included in the survival submodel. Moreover, we set method = "weibull-PH-GH" in
the function to apply the Weibull relative risk model in the regression of T1 .

4

Supplementary simulations for Chapter 3
In this supplementary information, we showed simulation results for the simple

SMART design in Figure S1, where all the subjects were randomized to two
interventions at both stages. Results are shown in Tables S7 and S8, which are
similar to Tables 14–17 for Figure 6. The results suggested that the proposed RCD
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method showed overall good performance, i.e., the RCD method effectively
allocated the subjects with respect to the final outcome values, covariate balance
and consistency of optimal Q-learning decisions. RD performed as well as RCD with
respect to the final outcomes and consistency of optimal Q-learning decisions, but
had higher percentage of significant imbalance of covariates, especially when
unequal randomization was applied to the first group in the trial.
Table S7 shows the simulation results for the SMART in Figure S1 with complete
randomization (with probability 0.5) applied to the first group of subjects in the trial.
Data were simulated by model (7) with parameter values:  20 =0.5 ,

 21 =0.5， 22 =-1， 23 =0.6 ,  24 =0.2， 20 =0.1， 21 =-0.1 and  22 =0.35 . O1 and O2 are
single covariates generated from normal distributions N (3,12 ) and N (0.1, 0.32 ) ,
respectively. The group size is 40 and the total sample size is 200. In this table, the
RCD and RD methods showed better performance than the other methods with
respect to the final outcome values and consistency of optimal Q-learning decisions,
i.e., ITN% was 31.79% and 33.22% under the RCD and RD methods, respectively;
both were lower than those values from the other methods; ODQ% was 69.54% and
68.41% under the RCD and RD methods, respectively; both were higher than those
values from the other methods. Meanwhile, RCD had lower percentage of
significant imbalance (i.e., 14.3%, 16.3%) than the RD and D methods, for which
the percentages of significant imbalance were 21.7%, 24.0% and 27.5%, 23.3%,
receptively.
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Table S8 shows the simulation results for Figure S1 with the same group size,
parameter values and distributions of O1 and O2 as that for Table S1, but the first
group of subjects were completely randomized (with probability 0.5). The results
were similar to those in Table S1, but RD and RCD both showed well controlled
covariate balance (i.e., RCD had 8.5% significant imbalance and RD had 10%). The
ITN% was 27.48% and 27.27% for the RCD and RD methods, respectively, which
was lower than the percentages obtained under the other methods. In addition,
ODQ% for RCD and RD was 71.92% and 71.88%, respectively, which was higher
than the percentages obtained under the other methods. In both Tables S7 and S8,
RC showed higher ITN% and ODQ% than the RCD and RD methods, but had much
lower percentage of significant covariate imbalance.
Tables S9 and S10 (S3 & S4) show the simulation results for the group size of
100 subjects (the total sample size is 500 subjects), with the first group randomized
according to their intermediate covariate (S9 and S3) and completely randomized
(S10 and S4). Although better performance with respect to ITN% and ODQ% (lower
ITN% and higher ODQ%) was obtained, we had much more severe imbalance of
covariates, especially for the methods (RCD, RD, CD, and D) we proposed. This is
because of the “over-skewed” allocation of subjects in the current group when the
group size is too large. In Table S9, the RCD and RD methods showed 27.8% and
28.89% for the ITN% and 73.61% and 73.56% for the ODQ%, respectively. They
both showed severe imbalance of covariates (i.e., 45.5%, 57.5% for RCD; 48.0%
and 63.0% for RD). All the other methods also showed higher percentage of
covariate imbalance than that in Table S7 because of the unequal randomization of
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the first group in the trial; whereas they all (except the method of total randomization)
had better ITN% and ODQ% estimations than that in Table S7. Similar results are
shown in Table S10, with lower ITN% and higher ODQ%; whereas higher
percentages of significant imbalance were obtained compared to those values in
Table S8.
In order to show the effect of the group size, we obtained the results of the
simulations with a group size of 20 (total sample size is 100) in Table S11 and S12.
(s5 and s6). The simulation setting for Table S11 was the same as that of Table S7
except for a smaller group size. All the methods showed much lower percentage of
significant imbalance than that in Table S7, except for the covariate-balance and
total randomization methods. RCD had 9.5% and 6% significant covariate
imbalance, while RD had 13% for both first-stage interventions. They had 35.8%
and 36.66% of ITN% and 65.28% and 64.57% of ODQ%, respectively, which were
both better than the percentages obtained from the other methods. In Table S12,
where the first group of subjects was completely randomized, all the methods
showed acceptable percentage of significant covariate imbalance; whereas RCD
and RD had better performance with respect to ITN% (34.46% and 35.11%,
respectively) and ODQ% (65.32% and 64.74%, respectively) than the other
methods. However, all the methods (except covariate-balance and total
randomization) showed higher ITN% and lower ODQ% than that in Table S8.
So, we can see that a smaller group size does ensure a better covariate
balance, but relatively more subjects are assigned to inferior intervention arms and
fewer subjects are assigned to the optimal Q-learning interventions in general.
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Supplemental Figures:

Figure 7S1. SMARTs in which the decision of whether to re-randomize or not
depends on an intermediate covariate and prior intervention
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Supplemental Tables:

Table S1. Eight embedded adaptive interventions in the SMART design of Figure 1.

(A1,A2R,A2NR)
(B,B,B+)

(B,B,B+M)

(B,B-,B+)

(B,B-,B+M)

(M,M,M+)

(M,M,B+M)

(M,M-,M+)

(1,1,1)

(1,1,-1)

(1,-1,1)

(1,-1,-1)

(-1,1,1)

(-1,1,-1)

(-1,-1,1)

Adaptive interventions
First, offer behavioral intervention; then continue
behavioral intervention for responders and increase the
intensity of behavioral intervention for non-responders.
First, offer behavioral intervention; then continue
behavioral intervention for responders and add
medication for non-responders.
First, offer behavioral intervention; then decrease the
intensity of behavioral intervention for responders and
increase the intensity of behavioral intervention for nonresponders.
First, offer behavioral intervention; then decrease the
intensity of behavioral intervention for responders and add
medication for non-responders.
First, offer medication; then continue medication for
responders and increase the intensity of medication for
non-responders.
First, offer medication; then continue medication for
responders and add behavioral intervention for nonresponders.
First, offer medication; then decrease the intensity of
medication for responders and increase the intensity of
medication for non-responders.

First, offer medication; then decrease the intensity of
medication for responders and add behavioral intervention
for non-responders.
M: medication; B: behavioral intervention; M+: intensified medication; B+: intensified
behavioral intervention; B+M: combined treatment of behavioral intervention and
medication
(M,M-,B+M)

(-1,-1,-1)
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Table S2. Four embedded adaptive interventions in the SMART of Figure 2.

(A1, A2NR)
(B,B+)

(B,B+M)

(M,M+)

(M,B+M)

(1, 1)

(1, 1)

(-1,1)

(-1,-1)

Adaptive interventions
First, offer behavioral intervention; then continue
behavioral intervention for responders and increase the
intensity of behavioral intervention for non-responders.
First, offer behavioral intervention; then continue
behavioral intervention for responders and add
medication for non-responders.
First, offer medication; then continue medication for
responders and increase the intensity of medication for
non-responders.
First, offer medication; then continue medication for
responders and add behavioral intervention for nonresponders.

.
Table S3. Longitudinal data organization

110

Table S4. The effect sizes associated with U1 and U2 (simulated two unmeasured
variables, U1 and U2 that affect the outcomes but were not included in the analyses)
influencing T1 and Y1 but not Y2

Panel A: The coefficients of unobserved confounders in the simulation model
U1

U2

T1

0.2

-0.3

Y1

-0.4

0.3

Y2

0

0

Panel B: Parameter estimation

12

 22

 23

32

(first-stage

(second-stage
interventions for

(second-stage
interventions for non-

(time of
intervention

interventions

A1 )

responders A2 R )

responders

A2 NR )

T2 )

True value
Estimate
Joint
MSE
Model
CI%
Length of CI

- 0.4
-0.391
0.011
98%
0.476

0.5
0.515
0.033
94%
0.688

0.4
0.389
0.016
96%
0.530

2.0
1.909
0.134
97%
1.464

Estimate
MSE
CI%
Length of CI

-0.508
0.023
89.5%
0.482

0.513
0.033
94%
0.706

0.389
0.017
96%
0.541

4.010
4.165
0%
1.446

TVMEM
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Table S5. The effect sizes associated with U1 and U2 influencing T1, Y1 and Y2

Panel A: coefficients of unobserved confounders in the simulation model
U1

U2

T1

0.2

-0.3

Y1

-0.4

0.3

Y2

-0.2

-0.3

Panel B: coefficients of unobserved confounders

12

 22

 23

32

(first-stage

(second-stage
interventions for

(second-stage
interventions for non-

(time of
intervention

interventions

A1 )

responders A2 R )

responders

A2 NR )

T2 )

True value
Estimate
Joint
MSE
Model
CI%
Length of CI

- 0.4
-0.391
0.010
98%
0.476

0.5
0.513
0.037
96%
0.689

0.4
0.396
0.015
97%
0.529

2.0
1.638
0.218
92%
1.458

Estimate
MSE
CI%
Length of CI

-0.505
0.021
90%
0.482

0.515
0.037
95%
0.707

0.395
0.015
97%
0.539

3.731
3.090
1%
1.441

TVMEM
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Table S6. The effect sizes associated with U1 and U2 influencing T1 and Y2 but not
Y1

Panel A: coefficients of unobserved confounders in the simulation model
U1

U2

T1

0.3

-0.4

Y1

0

0

Y2

0.2

-0.3

Panel B: coefficients of unobserved confounders

12

 22

 23

32

(first-stage

(second-stage
interventions for

(second-stage
interventions for non-

(time of
intervention

interventions

A1 )

responders A2 R )

responders

A2 NR )

T2 )

True value
Estimate
Joint
MSE
Model
CI%
Length of CI

- 0.4
-0.420
0.012
99%
0.477

0.5
0.490
0.035
91%
0.696

0.4
0.408
0.015
96%
0.529

2.0
2.210
0.163
94%
1.463

Estimate
MSE
CI%
Length of CI

-0.531
0.028
83%
0.483

0.491
0.037
91%
0.714

0.410
0.016
96%
0.539

4.263
5.232
0%
1.439

TVMEM
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Table S7. Simulation results based on 1000 replicates for SMART in Figure S1 with
parameter values  20 =0.5 ,  21 =0.5,  22 =-1,  23 =0.6,  24 =0.2,  20 =0.1,  21 =-0.1 and

 22 =0.35 ; The sample size was 200 with group sizes of 40; subjects in the first
group were assigned to the second-stage intervention based on their intermediate
covariate O2 (i.e., unequal randomization).

Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

31.79%

14.3%

16.3%

69.54%

RD

33.22%

21.7%

24.0%

68.41%

RC

37.71%

5.4%

3.8%

63.04%

CD

36.91%

13.7%

15.7%

64.78%

Total

49.93%

6.5%

5.0%

51.37%

D

37.16%

27.5%

23.0%

64.70%

R

37.63%

7.5%

7.0%

63.35%

C

50.11%

2.0%

3.7%

50.96%
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Table S8. Simulation results based on 1000 replicates for SMART in Figure S1 with
parameter values  20 =0.5 ,  21 =0.5,  22 =-1, ,  23 =0.6,  24 =0.2， 20 =0.1， 21 =-0.1
and  22 =0.35 ; the sample size was 200 with group sizes of 40; subjects in the first
group were assigned to the second-stage intervention completely at random (i.e.,
equal randomization).
Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

27.48%

8.5%

8.5%

71.92%

RD

27.27%

10.0%

10.0%

71.88%

RC

32.55%

2.5%

3.5%

66.57%

CD

35.68%

6.0%

7.5%

64.69%

Total

49.79%

4.5%

7.0%

50.15%

D

35.34%

15.0%

13.5%

64.95%

R

32.15%

3.5%

3.5%

66.88%

C

49.88%

2.5%

1.0%

49.96%
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Table S9. Simulation results based on 1000 replicates for SMART in Figure S1 with
parameter values  20 =0.5 ,  21 =0.5,  22 =-1,  23 =0.6,  24 =0.2,  20 =0.1,  21 =-0.1 and

 22 =0.35 ; The sample size was 500 with group sizes of 100; subjects were
assigned to the second-stage intervention based on their intermediate outcome O2
(i.e. unequal randomization).

Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

27.80%

45.5%

57.5%

73.61%

RD

27.89%

48.0%

63.0%

73.56%

RC

31.72%

6.5%

7.0%

68.83%

CD

29.47%

38.5%

46.5%

72.17%

Total

50.05%

11.0%

10.5%

51.36%

D

29.60%

42.0%

50.5%

72.24%

R

32.41%

15.5%

13.0%

68.45%

C

49.88%

4.5%

7.0%

51.88%
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Table S10. Simulation results based on 1000 replicates for SMART in Figure S1
with parameters  20 =0.5 ,  21 =0.5,  22 =-1, ,  23 =0.6,  24 =0.2， 20 =0.1， 21 =-0.1 and

 22 =0.35 ; the sample size was 500 with group sizes of 100; subjects were
assigned to the second-stage intervention completely at random (i.e., equal
randomization).

Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

21.80%

32.0%

40.5%

77.22%

RD

22.13%

35.2%

40.5%

76.92%

RC

24.14%

3.5%

3.5%

74.22%

CD

29.17%

19.4%

23.2%

71.53%

Total

50.09%

4.5%

7.0%

50.0%

D

29.16%

26.5%

29.1%

71.66%

R

24.13%

4.0%

3.0%

74.34%

C

50.02%

0.5%

0.1%

49.88%
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Table S11. Simulation results based 1000 replicates for SMART in Figure S1 with
parameter values  20 =0.5 ,  21 =0.5,  22 =-1,  23 =0.6,  24 =0.2,  20 =0.1,  21 =-0.1 and

 22 =0.35 ; the sample size was 100 with group sizes of 20; subjects were assigned
to the second-stage intervention based on their intermediate outcome O2 (i.e.,
unequal randomization).

Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

35.80%

9.5%

6.1%

65.28%

RD

36.66%

13.1%

13.2%

64.57%

RC

42.17%

2.4%

1.1%

48.65%

CD

40.75%

5.1%

5.2%

60.54%

Total

50.33%

5.3%

7.5%

50.99%

D

40.20%

15.0%

15.5%

61.33%

R

41.46%

6.2%

4.3%

59.76%

C

49.88%

4.5%

7.3%

51.45%
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Table S12. Simulation results based on 1000 replicates for SMART Figure S1 with
parameters  20 =0.5 ,  21 =0.5,  22 =-1, ,  23 =0.6,  24 =0.2， 20 =0.1， 21 =-0.1 and

 22 =0.35 ; the sample size was 100 with group sizes of 20; subjects were assigned
to the second-stage intervention completely at random (i.e., equal randomization).

Percentage of significant
ITN%

covariate imbalance
A1=1

A1=-1

ODQ%

RCD

34.46%

5.0%

5.3%

65.32%

RD

35.11 %

6.1%

5.3%

64.74%

RC

38.28%

3.1%

3.6%

61.11%

CD

40.63%

4.2%

4.3%

59.70%

Total

49.79%

5.3%

4.7%

50.10%

D

40.79%

5.4%

7.4%

59.51%

R

39.25%

2.4%

5.4%

60.23%

C

49.73%

2.0%

2.2%

50.25%
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